

CURRICULUM VITAE FOR
CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE

DATE: MARCH 30, 2023

PERSONAL INFORMATION

Name: Perez, Federico

Education

School: United World College of the American West
Degree: International Baccalaureate
Dates: September 1992- May 1994

School: Universidad del Valle School of Medicine
Degree: MD
Dates: September 1994- November 2001

School: Case Western Reserve University
Degree: MS, Clinical Research
Dates: September 2013- December 2017

Post-Graduate Training

Institution: University Hospitals Cleveland Medical Center, 11100 Euclid Av., Cleveland, Ohio
Position: Internal Medicine resident
Dates: July 2003 – June 2006

Institution: University Hospitals Cleveland Medical Center, 11100 Euclid Av., Cleveland, Ohio
Position: Infectious Diseases fellow
Dates: July 2006 – June 2009

Contact Information

Office Address: Louis Stokes Cleveland Department of Veterans Affairs Medical Center
Infectious Diseases 111 (w)
10701 East Boulevard, Cleveland, OH 44106

Office Phone: (216) 791 3800 x 66385

E-mail: federico.perez@va.gov; federico.perez@case.edu

Fax: (216) 229 2403

Home address: 2374 Roxboro Rd., Cleveland Heights, OH 44106

PROFESSIONAL APPOINTMENTS

Position/Rank: Physician and Researcher
Institution/Department: Louis Stokes Cleveland Department of Veterans Affairs Medical Center
Dates: July 2009 – present

Position/Rank: Director, Infectious Disease Fellowship Training Program
Institution/Department: University Hospitals Cleveland Medical Center/Louis Stokes Cleveland VA
Medical Center/MetroHealth Medical Center/Case Western Reserve University
Dates: July 2016 – present

Position/Rank: Faculty Scholar
Institution/Department: Louis Stokes Cleveland VA Medical Center Quality Scholars Program
Dates: January 2018 – July 2020

ACADEMIC APPOINTMENTS

Position/Rank: Associate Professor
Institution/Department: Case Western Reserve University School of Medicine/Department of Medicine
Dates: Effective July 1st 2018

Position/Rank: Assistant Professor
Institution/Department: Case Western Reserve University School of Medicine/Department of Medicine
Dates: January 2012 – June 2018

Position/Rank: Senior Instructor
Institution/Department: Case Western Reserve University School of Medicine/Department of Medicine
Dates: April 2011 – January 2012

CERTIFICATION AND LICENSURE

Name of Board: American Board of Internal Medicine – Certificate in Internal Medicine
Date of Certificate: 2006 – currently participating in maintenance of certification

Name of Board: American Board of Internal Medicine – Certificate in Internal Medicine
Date of Certificate: 2008 – currently participating in maintenance of certification

Licensure State/Number: *Doctor of Medicine* license by the State Medical Board of Ohio
Date Issued: 2006 – valid until 4/1/2024

HONORS AND AWARDS

Top graduate, Universidad del Valle School of Medicine, Class of 2001.

Simon Bolivar Award, Colombian Ministry of Education for obtaining the second highest score in the National Medical Graduates Examination, 2002.

Third Prize National “Best Intern” Competition, Colombian Association of Medical Schools, 2001.

Harold C. Klein, M.D. Award, for humaneness and caring of patients, University Hospitals Case Medical Center, 2006.

Infectious Diseases Fellow Travel Grant, Interscience Conference on Antimicrobial Agents and Chemotherapy, 2006-2008.

Infectious Diseases Society of America Fellow Travel Award, Infectious Diseases Society of America meeting, for excellence in abstract submission, 2007.

Chief Fellow, Division of Infectious Diseases and HIV Medicine, University Hospitals Case Medical Center, 2008-2009.

Wyeth Fellowship in Antimicrobial Resistance, Case Western Reserve University and University Hospitals Case Medical Center, 2008-2009.

Louis Stokes Scholar, Clinical and Translational Science Collaborative KL2 Program, 2012-2016.

Scholars Abstracts Award, Translational Science Conference, 2013.

Research Award Young Faculty Category, Department of Medicine, Case Western Reserve University School of Medicine, May 2013.

Scholarship in Teaching Award, Case Western Reserve University School of Medicine, March 2014.

Faculty Clerkship Teaching Award, Department of Medicine, Case Western Reserve University School of Medicine, May 2014.

Member of the Academy of Scholar Educators, Case Western Reserve University School of Medicine, April 2017.

Fellow, Infectious Diseases Society of America, April 2020.

Master Clinician Educator, Department of Medicine, Case Western Reserve University School of Medicine, May 2021.

MEMBERSHIP IN PROFESSIONAL SOCIETIES

Infectious Diseases Society of America

European Society for Clinical Microbiology and Infectious Diseases

American Society for Microbiology

PROFESSIONAL SERVICES

Member of the Editorial Advisory Board, *Open Forum Diseases*, 2019-2022

Associate Editor, *Clinical Infectious Diseases*, 2022

Treasurer, Veterans Administration Society of Practitioners of Infectious Diseases (VASPID), 2018-2020
Vice-president, Veterans Administration Society of Practitioners of Infectious Diseases (VASPID), 2021
Member Program Directors Committee, Infectious Diseases Society of America, 2016-2019
Member, Antimicrobial Drugs Advisory Committee, US Food and Drug Administration, 2020-2024

Ad-hoc Peer Reviewer for the following journals and organizations

Diagnostic Microbiology and Infectious Diseases, 2010 - present

Journal of Antimicrobial Chemotherapy, 2010 - present

Antimicrobial Agents and Chemotherapy, 2011 – present

Journal of Clinical Microbiology, 2011 - present

American Journal of Infection Control, 2012 - present

Microbial Drug Resistance, 2012 - present

Scandinavian Journal of Infectious Diseases, 2013 - present

Clinical Infectious Diseases, 2014 – present

International Journal of Antimicrobial Agents, 2014 – present

Lancet Infectious Diseases, 2014 – present

Open Forum Infectious Diseases, 2016-present

Journal of Global Antimicrobial Resistance, 2016-Present

Future Microbiology, 2017-Present

Commission of Privat-Docents, University of Geneva Faculty of Medicine, 2016

Health Research Board, Ireland, 2017

IDWeek Abstract reviewer, 2017-Present

Selection committee, Institutional KL2 Career Development Program, CWRU, 2017-Present

Wellcome Trust, United Kingdom, 2018

Medical Research Council, United Kingdom, 2019

COMMITTEE SERVICE

National

US Food and Drug Administration. Committee Name/Role: Antimicrobial Drugs Advisory Committee (formerly known as the Anti-Infective Drugs Advisory Committee)/member. Dates of service: 12/1/2020 – 11/30/2024

Infectious Diseases Society of America. Committee Name/Role: Program Directors Committee, member. Dates of service: 2016-2019

US Department of Veterans Affairs Office of Research and Development. Committee Name/Role: special emphasis panel (SEP) ZRD1 CSDR-Y1 for evaluation of COVID-19 clinical trials – October 23, 2020

Hospital affiliate

Committee Name/Role: Critical care council, member. Louis Stokes Cleveland VA Medical Center/member. Dates of Service: 2009 – present

School of Medicine

Committee Name/Role: Faculty search committee, member. Department of Microbiology and VA-CARES/member. Dates of Service: July 2018 – present

Committee Name/Role: Nominations and Elections Committee/member, Case Western Reserve University School of Medicine – 2020 - 2022.

Educational Committees

Committee Name/Role: Clinical competency committee, Infectious Diseases Fellowship University Hospitals Cleveland Medical Center/ Louis Stokes Cleveland VA Medical Center/Metrohealth Medical Center/chair. Dates of Service: 2015 – present

TEACHING ACTIVITIES

Curriculum/Course Development

1. “Augmenting the assessment of third year internal medicine clerkships through oral exams” - with Dr. Clifford Packer.
2. Infectious Diseases fellowship core curriculum
3. “Big Data” and clinical training of Infectious Diseases fellows, with Dr. Brigid Wilson

Local presentations

Undergraduate Students

1. *Lecturer* (1 hour). SAGEs seminar on *Antibiotics: from superdrug to superbug* (12/3/19 and 12/1/2020).

Medical Students

2. *Lecturer* (1 hour). Block 5, Medical school curriculum. Streptococci and streptococcal infections – CWRU School of Medicine (8/29/11, 9/1/12, 9/11/13, 9/5/14, 9/2/15, 8/31/16, 9/1/17, 9/1/18, 9/19, 9/20,). (Attended by second year medical students).
3. *Lecturer* (1 hour). Block 5, Medical school curriculum. Gram negative bacteria – CWRU School of Medicine (9/9/13, 9/5/14, 9/2/15, 9/1/16, 9/1/17, 9/1/18). (Attended by second year medical students).
4. *Lecturer* (1 hour). Block 5, Medical school curriculum. Prokaryotic organization – CWRU School of Medicine (9/9/13, 9/5/14, 9/2/15, 8/31/16, 9/1/17, 9/1/18, 8/21/19). (Attended by second year medical students).
5. *Moderator* (2 hours) IQ Plus session – CWRU School of Medicine (8/27/2010 and 9/11): Diabetic foot infection (Attended by 3rd year medical students).
6. *Leader* (2 hours) Medium Sized Groups – CWRU School of Medicine (9/10/2010 and 9/9/2011): Urinary tract infection and pneumonia (Attended by 2nd year medical students)
7. *Leader* (2 hours) Medium Sized Groups – CWRU School of Medicine (9/24/2010): Infection with mycobacteria other than tuberculosis and acute HIV infection (Attended by 2nd year medical students)
8. *Leader* (2 hours) Medium Sized Groups – CWRU School of Medicine (10/1/2010 and 9/23/11): Infection with coccidioidomycosis and renal transplantation (Attended by 2nd year medical students)
9. *Leader* (2 hours) Medium Sized Groups -CWRU School of Medicine (9/10/21 and 2022): Infection in immunosuppressed hosts
10. *Teaching Attending* – CWRU School of Medicine/Department of Medicine clerkship (1-2/2011): Sessions (2-hour duration, 2 days a week for 6 weeks) with medical students to discuss and refine H & P and PEs (Attended by 3rd year medical students).
11. *Lecturer* (1 hour) 3rd year Medical Student lecture series – Department of Medicine (6/17/09, 2/10/10, 6/16/10, 4/28/11, 8/23/11, 9/12, 3/13/15, 6/12/15, 12/2/2016, 3/17, 6/17, 3/9/18, 6/1/18, 9/28/18, 12/7/18, 3/15/19, 6/19, 9/19,3/20, 6/20, 9/20, 3/21, 9/21, 12/22, 3/22, 11/18/22): Antibiotics (Attended by 3rd year medical students)

Residents

1. *Lecturer* (½ hour). Internal Medicine Residents’ Noon Lecture - VAMC (1/6/10): Cholangitis (Attended by house staff)
2. *Lecturer* (½ hour). Internal Medicine Residents’ Noon Lecture - VAMC (2/16/10): Herpes zoster infection (Attended by house staff)
3. *Lecturer* (½ hour). Internal Medicine Residents’ Noon Lecture – VAMC (6/8/10): Necrotizing cellulitis and rhabdomyolysis. (Attended by house staff)
4. *Lecturer* (½ hour). Internal Medicine Residents’ Noon Lecture – VAMC (1/11): Endovascular infections and *Salmonella*. (Attended by house staff)
5. *Lecturer* (½ hour). Internal Medicine Residents’ Noon Lecture – VAMC (4/28/11): Latent tuberculosis infection. (Attended by house staff)
6. *Lecturer* (1 hour). Internal Medicine Resident’s Noon Lecture – VAMC (8/11/11): Pulmonary infection in a patient with AIDS (Attended by house staff and medical students).
7. *Lecturer* (1 hour). Internal Medicine Resident’s Noon Lecture – VAMC (1/6/12): Community acquired pneumonia (Attended by house staff and medical students).
8. *Lecturer* (1 hour). Internal Medicine Resident’s Noon Lecture – VAMC (5/14/12): Candida infection (Attended by house staff and medical students).
9. *Lecturer* (1 hour). Internal Medicine Resident’s Noon Lecture – VAMC (6/3/13): Community acquired pneumonia caused by Legionella (Attended by house staff and medical students).
10. *Lecturer* (1 hour). Internal Medicine Resident’s Noon Lecture – VAMC (1/8/14): Pulmonary infection in a patient with neutropenia (Attended by house staff and medical students).

11. *Lecturer* (1 hour). Internal Medicine Resident's Noon Lecture – VAMC (2/9/15): Bloodstream infection caused by ESBL-producing *Escherichia coli* after prostate biopsy (Attended by house staff and medical students).
12. *Lecturer* (1 hour). Internal Medicine Resident's Noon Lecture – VAMC (3/2/15): New antibiotics and strategies to administer antibiotics for the treatment of Gram-negative bacteria.
13. *Lecturer* (1 hour). Internal Medicine Resident's Noon Lecture – VAMC (12/29/15): Pneumococcal vaccines
14. *Lecturer* (1 hour). Internal Medicine Resident's Noon Lecture – VAMC (7/21/16): Procalcitonin
15. *Invited Lecture*: Peter Agre Society – UHCMC (2/7/18): Research in Antibiotic Resistance
16. *Lecturer* (1 hour). Internal Medicine Resident's Noon Lecture – VAMC (3/5/18): DRESS syndrome
17. *Lecturer* (1 hour). Internal Medicine Resident's Noon Lecture – VAMC (7/7/18): Cavitory lung lesion
18. *Lecturer* (1 hour). Internal Medicine Resident's Noon Lecture – VAMC (11/26/18): Neutropenic fever and lung mass
19. *Lecturer* (1 hour). Internal Medicine Resident's Noon Lecture – VAMC (1/6/19): Interesting stories in Infectious Diseases in 2018

Fellows

1. *Discussant* (30 min). Infectious Diseases Fellows Journal Club – UHCMC (11/12/09): Genetic susceptibility to infection. (Attended by ID fellows).
2. *Lecturer* (1 hour) Fellows' Lecture series – Division of Infectious Diseases and HIV Medicine (4/12/10; 2/22/16): Ocular infections (Attended by Infectious Diseases fellows).
3. *Lecturer* (1 hour) Fellows' Lecture series – Division of Infectious Diseases and HIV Medicine (1/17/11): Rare infections in U.S. common elsewhere: leptospirosis, leishmaniosis and Chagas disease. (Attended by Infectious Diseases fellows).
4. *Lecturer* (1 hour) Fellows' Lecture series – Division of Infectious Diseases and HIV Medicine (1/29/12): Candida. (Attended by Infectious Diseases fellows).
5. *Lecturer* (1 hour) Fellows' Lecture series – Division of Infectious Diseases and HIV Medicine (1/29/12): Candida. (Attended by Infectious Diseases fellows).
6. *Lecturer* (1 hour) Fellows' Lecture series – Division of Infectious Diseases and HIV Medicine (5/6/13): Pneumonia, antibiotics and study design. (Attended by Infectious Diseases fellows).
7. *Lecturer* (1 hour) Fellows' Lecture series – Division of Infectious Diseases and HIV Medicine (10/14/13): Treatment of infections caused by ESBL- and KPC producing *Enterobacteriaceae*. (Attended by Infectious Diseases fellows).
8. *Lecturer* (1 hour) Fellows' Lecture series – Division of Infectious Diseases and HIV Medicine (10/20/14): Antibiotic resistant Gram-negative bacterial infections in patients with cancer. (Attended by Infectious Diseases fellows).
9. *Lecturer* (1 hour) Fellows' Lecture series – Division of Infectious Diseases and HIV Medicine (5/15/15): Global Surveillance of Antibiotic Resistant Gram-negative bacteria. (Attended by Infectious Diseases fellows).
10. *Lecturer* (1 hour) Fellows' Lecture series – Division of Infectious Diseases and HIV Medicine (1/31/17; 5/1/20): Cases in Antibiotic Resistance (Attended by Infectious Diseases fellows).
11. *Lecturer* (1 hour) Fellows' Lecture series – Division of Infectious Diseases and HIV Medicine (2/8/17, 10/8/18 and 9/21): Endocarditis (Attended by Infectious Diseases fellows).
12. *Lecturer* (1 hour) Fellows' Lecture series – Division of Infectious Diseases and HIV Medicine (8/21/17): Bloodstream infections (Attended by Infectious Diseases fellows).
13. *Lecturer* (1 hour) Fellows' Lecture series – Division of Infectious Diseases and HIV Medicine (9/18/17): Candida (Attended by Infectious Diseases fellows).
14. *Lecturer* (1 hour) Fellows' Lecture series – Division of Infectious Diseases and HIV Medicine (10/30/17; 10/19): Eye infections (Attended by Infectious Diseases fellows).
15. *Lecturer* (1 hour) Fellows' Lecture series – Division of Infectious Diseases and HIV Medicine (12/20/17): The year in ID: important papers (Attended by Infectious Diseases fellows).
16. *Lecturer* (1 hour) Fellows' Lecture series – Division of Infectious Diseases and HIV Medicine (1/13/19): Interesting stories in Infectious Diseases in 2018 (Attended by Infectious Diseases fellows).
17. *Lecturer* (1 hour) Fellows' Lecture series – Division of Infectious Diseases and HIV Medicine (4/7/19): Active surveillance for MRSA and CRE (Attended by Infectious Diseases fellows).

Continuing medical education

1. *Discussant* (½ hour). Morbidity and Mortality Conference – VAMC (7/8/09): *Streptococcus gordonii* prosthetic valve endocarditis. (Attended by physicians, house staff and medical students).
2. *Discussant* (½ hour). Morbidity and Mortality Conference – VAMC (10/2/09): *Pantoea* spp. bacteremia. (Attended by physicians, house staff and medical students).
3. *Discussant* (½ hour). Morbidity and Mortality Conference – VAMC (4/14/10): Septic arthritis. (Attended by physicians, house staff and medical students).
4. *Discussant* (½ hour). Morbidity and Mortality Conference – VAMC (6/23/10): Infection in the immunocompromised host. (Attended by physicians, house staff and medical students).
5. *Discussant* (½ hour). Morbidity and Mortality Conference – UHCMC (2/5/10): *Acinetobacter* infection in a transplant patient. (Attended by physicians, house staff and medical students).
6. *Discussant* (½ hour). Morbidity and Mortality Conference – VAMC (7/7/11): Infection in a patient with Myelodysplastic Syndrome. (Attended by physicians, house staff and medical students).
7. *Discussant* (½ hour). Morbidity and Mortality Conference – VAMC (1/18/12): Aspergilloma and chronic invasive aspergillosis. (Attended by physicians, house staff and medical students).
8. *Discussant* (½ hour). Morbidity and Mortality Conference – VAMC (2/27/12): Gonococcus and joint disease. (Attended by physicians, house staff and medical students).
9. *Discussant* (½ hour). Morbidity and Mortality Conference – VAMC (8/1/12): Diarrhea and salmonellosis. (Attended by physicians, house staff and medical students).
10. *Discussant* (½ hour). Morbidity and Mortality Conference – VAMC (12/19/12): MRSA bacteremias and vascular graft infection. (Attended by physicians, house staff and medical students).
11. *Discussant* (½ hour). Morbidity and Mortality Conference – UHCMC (1/4/13): KPC-producing *Klebsiella pneumoniae* in a cancer patient. (Attended by physicians, house staff and medical students).
12. *Discussant* (½ hour). Morbidity and Mortality Conference – VAMC (11/6/13): Invasive Aspergillosis: the bug, the host and the drug. (Attended by physicians, house staff and medical students).
13. *Discussant* (½ hour). Morbidity and Mortality Conference – VAMC (11/6/13): Necrotizing fasciitis caused by *Escherichia coli*. (Attended by physicians, house staff and medical students).
14. *Discussant* (½ hour). Morbidity and Mortality Conference – VAMC (1/29/14): Airway in a patient with oral cancer. (Attended by physicians, house staff and medical students).
15. *Discussant* (½ hour). Morbidity and Mortality Conference – VAMC (6/12/15): Subacute bacterial endocarditis (Attended by physicians, house staff and medical students).
16. *Discussant* (½ hour). Morbidity and Mortality Conference – VAMC (4/23/16): Fulminant *Clostridium difficile* colitis (Attended by physicians, house staff and medical students)
17. *Discussant* (½ hour). Morbidity and Mortality Conference – VAMC (11/9/16): Literature review: ID (Attended by physicians, house staff and medical students)
18. *Discussant* (½ hour). Morbidity and Mortality Conference – VAMC (12/17/16): Cryptococcal meningitis and AIDS (Attended by physicians, house staff and medical students)
19. *Discussant* (½ hour). Morbidity and Mortality Conference – UHCMC (2/10/17): *Candida* and *Staphylococcus aureus* bloodstream infection and their perilous sequelae (Attended by physicians, house staff and medical students)
20. *Discussant* (½ hour). Morbidity and Mortality Conference – VAMC (2/23/17): *Escherichia coli* necrotizing skin and soft tissue infection (Attended by physicians, house staff and medical students)
21. *Discussant* (½ hour). Morbidity and Mortality Conference – VAMC (9/6/17): *Campylobacter coli* bloodstream infection (Attended by physicians, house staff and medical students)
22. *Discussant* (½ hour). Morbidity and Mortality Conference – UHCMC (1/5/18): Endocarditis in people who inject drugs (Attended by physicians, house staff and medical students)
23. *Discussant* (½ hour). Morbidity and Mortality Conference – VAMC (5/16/18): Steroids in septic shock (Attended by physicians, house staff and medical students)
24. *Discussant* (½ hour). Morbidity and Mortality Conference – VAMC (9/5/18): Sepsis syndrome and rhabdomyolysis (Attended by physicians, house staff and medical students)
25. *Discussant* (½ hour). Morbidity and Mortality Conference – VAMC (4/17/19): Legionellosis in a cardiac transplant patient (Attended by physicians, house staff and medical students)

26. *Discussant* (½ hour). Morbidity and Mortality Conference – VAMC (6/12/19): Infections in people who inject drugs (Attended by physicians, house staff and medical students)
27. *Discussant* (½ hour). Morbidity and Mortality Conference – VAMC (2/12/20): Coronavirus disease 2019 (Attended by physicians, house staff and medical students)
28. *Discussant* (½ hour). Morbidity and Mortality Conference – VAMC (2/26/20): Community acquired pneumonia guidelines (Attended by physicians, house staff and medical students)
29. *Discussant* (½ hour). Morbidity and Mortality Conference – VAMC (1/19/23): CNS infection with blastomyces (Attended by physicians, house staff and medical students)

Grand Rounds

1. Infectious Diseases Grand Rounds, Cleveland Clinic Foundation – (10/13/10): Re-discovering Multidrug Resistant Gram-negative bacteria (Attended by ID physicians, 1 hour).
2. Department of Medicine Grand Rounds, University Hospitals Case Medical Center – (12/7/10): Responding to the threat of antibiotic resistant Gram-negative bacteria. (Attended by physicians, house staff and medical students)
3. Department of Medicine Research Day, University Hospitals Case Medical Center – (5/16/11): Plenary speaker - Investigations in antibiotic resistance: a young clinician's perspective.
4. Division of Rheumatology Grand Rounds, University Hospitals Case Medical Center – (2/2/12): Update in Antibiotics
5. Department of Medicine Grand Rounds, University Hospitals Case Medical Center – (2/4/14): Extensively drug resistant (XDR) *Pseudomonas aeruginosa*: a new challenge in our midst.
6. Emmanuel Wolinsky Series, Department of Medicine, MetroHealth Medical Center – (11/7/14): Extensively drug resistant (XDR) *Pseudomonas aeruginosa*: a new challenge in our midst.
7. Department of Medicine Grand Rounds, Fairview Hospital – (1/25/16): Extensively drug resistant (XDR) Gram negative bacteria.
8. Infectious Diseases and Microbiology Grand Rounds, University Hospital and University of Western Ontario School of Medicine – (2/20/18): Evidence for the treatment of carbapenem-resistant Gram-negative bacteria.
9. Infectious Diseases Grand Rounds, Cleveland Clinic – (11/6/19): *Pseudomonas aeruginosa*
10. Infectious Diseases Grand Rounds, Cleveland Clinic – (10/6/21): And how long tetracyclines?
11. Medicine Grand Rounds, Cleveland Clinic – (12/3/21): Vaccines to fight antimicrobial resistance
12. Medical Education Grand Rounds, Case Western Reserve University School of Medicine – (11/2/22): Why should you review a paper for a medical journal?

Regional conferences

1. Northeast Ohio Infectious Diseases Roundtable – (11/18/09): Bugs and drugs: highlights in antimicrobial resistance from IDSA/ICAAC (Attended by local ID physicians, ½ hour).
2. Cleveland Ophthalmological Society Meeting – (4/13/10): The new face of ocular infections (Attended by local ophthalmologists, ½ hour).
3. Infectious Diseases Update, Parma General Hospital – (10/13/10): Update on Multidrug Resistant Gram-negative bacteria (Attended by ID physicians and infection control practitioners).
4. Sport Fellowship Lecture Series, Sport Health Center Cleveland – (11/5/10): Infectious Diseases and athletes (Attended by physical therapists and sport physicians, 15 minutes).
5. Steris Corporation Infection Control Summit, (9/11): MRSA Initiative at VA (Attended by Infection control practitioners, 30 minutes).
6. Antibiotic Resistance Workshop Detroit (10/11), session moderator (Attended by Infection control practitioners, 30 minutes).
7. Northeast Ohio Infectious Diseases Roundtable – (11/16/11): Is there and end in sight to the crisis?: New antibiotics from 51st ICAAC. (Attended by local ID physicians, ½ hour).
8. Northeast Ohio Infectious Diseases Roundtable – (11/14/12): Bad bugs, no drugs: New antibiotics from 52nd ICAAC. (Attended by local ID physicians, ½ hour).

9. Lecture for ID fellows at Cleveland Clinic – (4/3/13): Molecular Surveillance of Carbapenem Resistant Organisms: Emergence of High-Risk Clones in Northeast Ohio. (Attended by ID fellows and faculty, ½ hour).
10. Speaker at the Ohio Association for Advanced Practice Nurses Statewide Conference – (10/25/14): Antibiotic stewardship. (Attended by Advanced Nurse Practitioners)
11. Northeast Ohio Infectious Diseases Roundtable – (3/6/16): Colistin Resistance in Enterobacteriaceae. (Attended by regional ID physicians, ½ hour)
12. 16th Annual Spinal Cord Injury Conference at Cleveland VAMC – (10/16): Pneumonia in patients with SCI (Attended by SCI nurses and physicians 45 minutes).
13. Infectious Diseases Society of Ohio (4/22/17): Update in antibiotic resistance in Gram negative bacteria. (Attended by ID physicians from the state of Ohio, 45 minutes).
14. 17th Annual Spinal Cord Injury Conference at Cleveland VAMC – (10/28/17): Osteomyelitis in patients with SCI (Attended by SCI nurses and physicians 45 minutes).
15. Meeting of the Northeastern Ohio Association of Clinical Microbiologists (TIIMS Group), SouthPoint Hospital, (3/15/18): “Diagnosing Sepsis and Bacteremia: A Clinician’s Perspective” (Attended by clinical microbiologists and laboratory technicians).
16. VISN10 GRECC Topics lecture (3/6/20): COVID-19 and SARS-CoV-2 epidemic (Broadcast regionally and nationally).

National conferences

1. Speaker, Sixth Annual Conference on Molecular Diagnostics for Infectious Disease, Washington DC - (8/20 - 21, 2014): “Salvage Microbiology”—Identifying Pathogens in Culture Negative Infections
2. Speaker, Fifth International Conference on Global Health, Miami, FL – (5/20-22, 2015): “Antimicrobial Resistance Surveillance and its Impact in the Americas”
3. Speaker, IDWeek 2016, New Orleans (10/26-30, 2016): Polymyxin resistance
4. Speaker, IDWeek 2016, New Orleans (10/26-30, 2016): Metallo-beta-lactamase producing *P. aeruginosa*
5. Moderator, IDWeek, 2016, New Orleans (10/26-30, 2016): Session on Bacteremia
6. Moderator, IDWeek, 2017, San Diego (10/4-8, 2017): Session on Bacteremia
7. Speaker, IDWeek 2018, San Francisco (10/3-7, 2018): Meropenem-vaborbactam and its current role
8. Moderator, IDWeek 2019, Washington (10/2-6, 2019): Press conference: Antibiotic-free or organic poultry half as likely to be contaminated with multidrug-resistant Salmonella

International conferences

9. Lecturer, Molecular Pathogenesis of Gram negative bacteria, Symposium of the National Academy of Science and Technology, National Institute of Health, University of the Philippines, Manila, Philippines – (2/20/2015): Who is winning the antibiotics arms race?: The current status of our battle against *Acinetobacter baumannii*.
10. Speaker, 53rd State of the Art Conference “Contagion: Epidemics and emerging infections”, Philippine Society for Microbiology and Infectious Diseases, Manila, Philippines – (2/22/15): Multidrug resistant, extensively drug resistant and pandrug resistant Gram-negative bacteria. (Attended by ID doctors and critical care doctors)
11. Speaker, 53rd State of the Art Conference “Contagion: Epidemics and emerging infections”, Philippine Society for Microbiology and Infectious Diseases, Manila, Philippines – (2/23/15): Future antimicrobial agents and treatment strategies for Gram negative bacteria. (Attended by ID doctors and critical care doctors)
12. Speaker, 12th meeting of the Colombian Infectious Diseases Society, Bogota, Colombia (8/13/15): MDR/PDR Gram negative bacteria: are there any treatment options? (Attended by ID doctors)
13. Speaker, 12th meeting of the Colombian Infectious Diseases Society, Bogota, Colombia (8/13/15): *Acinetobacter baumannii*: why are we afraid? (Attended by ID doctors)
14. Speaker, II Polymyxins Conference (9/22-9/24/15): How do Gram negative bacteria escape polymyxin killing? San Diego CA.
15. Speaker, 13th Annual Meeting of the Chilean Collaborative Bacterial Resistance Group, Santa Cruz, Chile (3/31/17): New developments in antibiotic resistance in Gram negative rods
16. Speaker, 13th Annual Meeting of the Chilean Collaborative Bacterial Resistance Group, Santa Cruz, Chile (4/1/17): Utility of whole genome sequencing in diagnosing antibiotic resistance”

17. Speaker, 13th Annual Meeting of the Chilean Collaborative Bacterial Resistance Group, Santa Cruz, Chile (4/1/17): Beyond colistin: new antibiotic against resistant Gram-negative rods
18. Podium presentation, 28th European Congress of Clinical Microbiology and Infectious Diseases, Madrid, Spain (4/21/18): INCREMENT score predicts mortality in patients with carbapenem-resistant *Enterobacter cloacae* complex bloodstream infections from the VHA
19. Speaker, III Polymyxins Conference, Madrid, Spain (4/26/18): Clinical Impact of Colistin Resistance
20. Speaker, XXV Colombian Congress on Internal Medicine Cali, Colombia (8/16-18/18): Combination therapy against Gram negative bacteria and the threat of Acinetobacter
21. Speaker, VIII International Symposium on Hospital Acquired Infections and Antimicrobial Stewardship, Cali Colombia (3/27-3/29/19): Active surveillance against MRSA and CRE
22. Speaker, VIII International Symposium on Hospital Acquired Infections and Antimicrobial Stewardship, Cali, Colombia (3/27-3/29/19): Challenging cases in antimicrobial resistance
23. Speaker, 14th meeting of the Colombian Infectious Diseases Society and 18th Meeting of the Latin American Society of Pediatric Infectious Diseases, Cartagena de Indias, Colombia (8/23-24/19): Management of infection in the era of multidrug resistance
24. Speaker, 14th meeting of the Colombian Infectious Diseases Society and 18th Meeting of the Latin American Society of Pediatric Infectious Diseases, Cartagena de Indias, Colombia (8/23-24/19): Challenging cases in MDR organisms: Pseudomonas aeruginosa
25. Speaker, University Course of Bacterial Resistance, Santiago de Chile, Chile (8/26-27/19): Pseudomonas aeruginosa and advances in resistance mechanisms
26. Speaker, University Course of Bacterial Resistance, Santiago de Chile, Chile (8/26-27/19): New molecules in development to treat Gram-negative rods
27. Speaker, World Microbe Forum (6/20-6/24/21): And how long tetracyclines?
28. Speaker, World Microbe Forum (6/20-6/24/21): Literature Review
29. Speaker, Pre-ECCMID Day on Antimicrobial Resistance (6/30/21): New and old beta-lactamase inhibitors.
30. Speaker, 15th meeting of the Colombian Infectious Diseases Society (9/2/21): Surveillance and therapeutic choices.
31. Speaker, 15th meeting of the Colombian Infectious Diseases Society (9/2/21): Zero bacteremias
32. Speaker, XIII International Symposium on Bacterial Resistance (3/18/22): Emerging mechanisms of resistance in Gram-negative bacteria: from diagnosis and therapy to prevention
33. Speaker, Colombian Infectious Diseases Society, SW Section (9/22/22): What is new in carbapenemases?

Trainees / Mentees

1. Nathan Summers, MD, Internal Medicine resident, 2015, University Hospitals Cleveland Medical Center
2. Leanne Moore, PharmD resident, 2015, Louis Stokes Cleveland VAMC
3. Max Feinstein, medical student, 2016, CWRU School of Medicine
4. Patricia Bartley, Infectious Diseases fellow, 2016, University Hospitals Cleveland Medical Center
5. Nadim El Chakhtoura, Infectious Diseases fellow, 2016, University Hospitals Cleveland Medical Center
6. Sachin Patel, Infectious Diseases fellow, 2016, University Hospitals Cleveland Medical Center
7. Patricia Bartley, Infectious Diseases fellow, 2016, University Hospitals Cleveland Medical Center
8. Anubhav Kanwar, Infectious Diseases fellow, 2017, University Hospitals Cleveland Medical Center
9. Mohamad Yasmin, Infectious Diseases fellow, 2017, University Hospitals Cleveland Medical Center
10. Rishi Sharma, Infectious Diseases fellow, 2018, University Hospitals Cleveland Medical Center
11. David C. Nguyen, Infectious Diseases fellow, 2019, University Hospitals Cleveland Medical Center
12. Sonya Khotadia, Infectious Diseases fellow, 2019, University Hospitals Cleveland Medical Center
13. Nicole Mongilardi, Infectious Diseases fellow, 2019, University Hospitals Cleveland Medical Center
14. Todd Chengsupanimit, Internal Medicine Resident, 2022, University Hospitals Cleveland Medical Center
15. May Al-Abdely, Internal Medicine Resident, 2022, University Hospitals Cleveland Medical Center

Teaching Material Produced

1. Oral examination conducted at end of medicine rotation at VAMC – every 3 months throughout year (Activity coordinated by Dr. Clifford Packer).
2. Infectious Diseases fellowship core curriculum
3. “Big Data” and clinical training of Infectious Diseases fellows

Teaching Administration

1. Program director, Infectious Diseases fellowship program, Case Western Reserve University/University Hospitals Cleveland Medical Center/Louis Stokes Cleveland VA Medical Center/MetroHealth Medical Center.

Teaching Activities (see above for lectures given to trainees)

1. Attending physician, Inpatient Medicine service – 1 senior resident, 2 interns, +/- 2 medical students, Louis Stokes Cleveland VA Medical Center – approximately 6 weeks a year
2. Attending physician, Infectious Diseases consultation service – 1 fellow +/- medical students, pharmacy or podiatry residents, Louis Stokes Cleveland VA Medical Center –approximately 6 weeks a year

RESEARCH SUPPORT

Past

1. *STERIS Corporation* Internal Seed Grant. July 2009 – July 2011. \$37,500 direct costs. The aims were: 1) to survey and determine the genetic basis of resistance among carbapenem resistant organisms from acute care and long-term care facilities in Cleveland
2. *Career Development Award, KL2 - Clinical Translational Science Collaborative/National Institutes of Health*, July 2012 – July 2016. The aims of the proposal were to develop as an independent investigator in infectious diseases and antimicrobial resistance and to investigate the clinical and molecular determinants of infection with carbapenem resistant pathogens in hospitalized patients
3. *Pfizer Independent Grants for Learning and Changing*. Reducing Disparities in Pneumococcal Vaccination among Ohio Veterans. The goal was to understand the vaccination among veterans at risk for invasive pneumococcal disease. PIs: Federico Perez and Robin L. Jump. July 2014- July 2016. \$250,000.
4. *Merck*. Real-world Clinical use of ceftolozane/tazobactam for the treatment of Gram-negative infections in Northeast Ohio and Southeast Michigan. The goal of this project is to compare the effectiveness of ceftolozane/tazobactam to colistin based regimens for the treatment of Gram-negative bacterial infections. PIs: Federico Perez and Jason Pogue. April 2017 - December 2018. \$304,000.
5. *Pfizer*. Epidemiology and Risk Factors for Group B Streptococcal Infections Among Veterans. The overall goal for this project is to use the using the VA’s robust and comprehensive databases to identify populations most at risk for both invasive and non-invasive GBS infections. PIs: Federico Perez and Robin L. Jump. January 2018- December 2019. \$237,000.
6. *Pfizer*. Burden of Community-Acquired Pneumonia in the Veterans Affairs Population in 2016-2017. The goals of this project are to determine the incidence of community-acquired pneumonia occurring among Veterans, with stratification by age, risk group and geographic region. PIs: Federico Perez and Robin L. Jump. January 2019 – December 2019. \$204,100.
7. *Accelerate Diagnostics*. Analysis of Real-World Outcomes and Practices in Treating Patients with Hospital-Acquired Bacterial Pneumonia. The goals of this project are to evaluate the timing of microbiological tests pertaining to samples obtained by bronchoscopy from veterans diagnosed with hospital-acquired pneumonia and to assess the potential for influence of rapid diagnostics to influence the use of antibiotics for those patients. PIs: Federico Perez and Robin L. Jump. January 2019 – December 2019. \$55,250.
8. *Merck*. Outpatient *Clostridioides difficile* and resistant bacteria from antibiotic prescribing. The goal of this project is to test the use of comparative feedback reports that make making unintended consequences of antibiotic prescriptions visible to prescribing clinicians on their overall antibiotic use. PIs: Federico Perez and Robin L. Jump. January 2020 – December 2021. \$250,700.
9. *Locus Research*: A multi-center randomized, double-blind study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of a cocktail of bacteriophages modified with CPRISPR (Ibpec01) in patients with lower urinary tract colonization caused by *E. coli*. Site PI: Federico Perez – June 2020 – February 2021. \$151,935 (closed early)
10. *VA ORD CSP*: VA Coronavirus Research and Efficacy Studies -1 (VA-CURES-1): nationwide multi-center, randomized, double-blind, placebo-controlled trial (RCT) among veterans hospitalized with COVID-19 and

requiring supplemental oxygen to test the efficacy and safety of convalescent plasma. LSI/Co-LSI: Usha Stiefel and Federico Perez.

Active Research Projects

11. *Pfizer*: A phase 1/2/3 placebo controlled randomized observer blind dose finding study to describe the safety tolerability, immunogenicity and potential efficacy of SARS-CoV-2 vaccine candidates against Covid-19 in healthy adults. Site co-I: Federico Perez
12. *VA ORD CSP*: VHA CSP #2028: Epidemiology, Immunology and Clinical Characteristics of COVID-19 (EPIC3) within the Veterans Health Administration study. LSI: Federico Perez.
13. *VA CSRD*: Patient Movement and Impact on Multidrug-Resistant Organism (MDRO) Transmission. LSI: Federico Perez
14. *AHRQ*: Developing a novel antibiogram tool to improve empiric antibiotic prescribing in nursing homes. LSI: Federico Perez.
15. *VA ORD HSRD*: Dissemination and Implementation of a Videoconference Antimicrobial Stewardship Team (VAST). LSI: Federico Perez
16. *CDC and VA ORD*: Expanded Access IND Protocol: Use of Tecovirimat (TPOXX®) for Treatment of Human Orthopoxvirus Infections. PI: Curtis Donskey; Co-PI: Federico Perez
17. *VA ORD CSP*: VHA CSP #596: Optimal Treatment for Recurrent *Clostridium difficile* Infection (OPTION). LSI: Federico Perez.

BIBLIOGRAPHY

Peer Reviewed Articles

1. Villegas MV, Correa A, **Perez F**, Zuluaga T, Radice M, et al. CTX-M-12 beta-lactamase in a *Klebsiella pneumoniae* clinical isolate in Colombia. *Antimicrob Agents Chemother*. 2004 Feb;48(2):629-31. PubMed PMID: [14742223](#); PubMed Central PMCID: [PMC321560](#).
2. Villegas MV, Correa A, **Perez F**, Miranda MC, Zuluaga T, et al. Prevalence and characterization of extended-spectrum beta-lactamases in *Klebsiella pneumoniae* and *Escherichia coli* isolates from Colombian hospitals. *Diagn Microbiol Infect Dis*. 2004 Jul;49(3):217-22. PubMed PMID: [15246513](#).
3. Hujer KM, Hamza NS, Hujer AM, **Perez F**, Helfand MS, et al. Identification of a new allelic variant of the *Acinetobacter baumannii* cephalosporinase, ADC-7 beta-lactamase: defining a unique family of class C enzymes. *Antimicrob Agents Chemother*. 2005 Jul;49(7):2941-8. PubMed PMID: [15980372](#); PubMed Central PMCID: [PMC1168656](#).
4. Miranda MC, **Pérez F**, Zuluaga T, Olivera Mdel R, Correa A, et al. [Antimicrobial resistance in gram negative bacteria isolated from intensive care units of Colombian hospitals, WHONET 2003, 2004 and 2005]. *Biomedica*. 2006 Sep;26(3):424-33. PubMed PMID: [17176006](#).
5. **Perez F**, Hujer AM, Hujer KM, Decker BK, Rather PN, et al. Global challenge of multidrug-resistant *Acinetobacter baumannii*. *Antimicrob Agents Chemother*. 2007 Oct;51(10):3471-84. PubMed PMID: [17646423](#); PubMed Central PMCID: [PMC2043292](#).
Seminal review on the mechanisms of resistance, clinical impact and treatment of Acinetobacter baumannii, a multidrug resistance Gram negative bacteria par excellence. Cited >1600 times according to Google Scholar.
6. **Perez F**, Endimiani A, Hujer KM, Bonomo RA. The continuing challenge of ESBLs. *Curr Opin Pharmacol*. 2007 Oct;7(5):459-69. PubMed PMID: [17875405](#); PubMed Central PMCID: [PMC2235939](#).
7. **Perez F**, Salata RA, Bonomo RA. Current and novel antibiotics against resistant Gram-positive bacteria. *Infect Drug Resist*. 2008; 1:27-44. PubMed PMID: [21694878](#); PubMed Central PMCID: [PMC3108725](#).
8. **Perez F**, Endimiani A, Bonomo RA. Why are we afraid of *Acinetobacter baumannii*?. *Expert Rev Anti Infect Ther*. 2008 Jun;6(3):269-71. PubMed PMID: [18588489](#); PubMed Central PMCID: [PMC4085750](#).
9. Endimiani A, Carias LL, Hujer AM, Bethel CR, Hujer KM, **Perez F**, et al. Presence of plasmid-mediated quinolone resistance in *Klebsiella pneumoniae* isolates possessing *bla_{KPC}* in the United States. *Antimicrob Agents Chemother*. 2008 Jul;52(7):2680-2. PubMed PMID: [18426899](#); PubMed Central PMCID: [PMC2443894](#).
10. Endimiani A, **Perez F**, Bonomo RA. Cefepime: a reappraisal in an era of increasing antimicrobial resistance. *Expert Rev Anti Infect Ther*. 2008 Dec;6(6):805-24. PubMed PMID: [19053894](#); PubMed Central PMCID: [PMC2633657](#).

11. Endimiani A, Hujer AM, **Perez F**, Bethel CR, Hujer KM, et al. Characterization of *bla*_{KPC}-containing *Klebsiella pneumoniae* isolates detected in different institutions in the Eastern USA. *J Antimicrob Chemother.* 2009 Mar;63(3):427-37. PubMed PMID: [19155227](#); PubMed Central PMCID: [PMC2640158](#).
12. Rodríguez-Baño J, García L, Ramírez E, Martínez-Martínez L, Muniain MA, ...**Perez F**, et al. Long-term control of hospital-wide, endemic multidrug-resistant *Acinetobacter baumannii* through a comprehensive "bundle" approach. *Am J Infect Control.* 2009 Nov;37(9):715-22. PubMed PMID: [19457584](#); PubMed Central PMCID: [PMC2783564](#).
13. Endimiani A, Depasquale JM, Forero S, **Perez F**, Hujer AM, et al. Emergence of *bla*_{KPC}-containing *Klebsiella pneumoniae* in a long-term acute care hospital: a new challenge to our healthcare system. *J Antimicrob Chemother.* 2009 Nov;64(5):1102-10. PubMed PMID: [19740911](#); PubMed Central PMCID: [PMC2760463](#).
14. Endimiani A, Patel G, Hujer KM, Swaminathan M, **Perez F**, et al. In vitro activity of fosfomycin against *bla*_{KPC}-containing *Klebsiella pneumoniae* isolates, including those nonsusceptible to tigecycline and/or colistin. *Antimicrob Agents Chemother.* 2010 Jan;54(1):526-9. PubMed PMID: [19901089](#); PubMed Central PMCID: [PMC2798518](#).
15. **Perez F**, Hujer AM, Hulten EA, Fishbain J, Hujer KM, et al. Antibiotic resistance determinants in *Acinetobacter* spp and clinical outcomes in patients from a major military treatment facility. *Am J Infect Control.* 2010 Feb;38(1):63-5. PubMed PMID: [19783325](#); PubMed Central PMCID: [PMC4085753](#).
16. Guerrero DM, **Perez F**, Conger NG, Solomkin JS, Adams MD, et al. *Acinetobacter baumannii*-associated skin and soft tissue infections: recognizing a broadening spectrum of disease. *Surg Infect (Larchmt).* 2010 Feb;11(1):49-57. PubMed PMID: [19788383](#); PubMed Central PMCID: [PMC2956563](#).
17. **Perez F**, Endimiani A, Ray AJ, Decker BK, Wallace CJ, et al. Carbapenem-resistant *Acinetobacter baumannii* and *Klebsiella pneumoniae* across a hospital system: impact of post-acute care facilities on dissemination. *J Antimicrob Chemother.* 2010 Aug;65(8):1807-18. PubMed PMID: [20513702](#); PubMed Central PMCID: [PMC2904665](#).
This description of system-wide outbreak of carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae contributed to define the role of long term care facilities in the epidemic of multidrug resistant organisms.
18. Endimiani A, **Perez F**, Bajaksouzian S, Windau AR, Good CE, et al. Evaluation of updated interpretative criteria for categorizing *Klebsiella pneumoniae* with reduced carbapenem susceptibility. *J Clin Microbiol.* 2010 Dec;48(12):4417-25. PubMed PMID: [20881179](#); PubMed Central PMCID: [PMC3008460](#).
19. Patel G, **Perez F**, Bonomo RA. Carbapenem-resistant *Enterobacteriaceae* and *Acinetobacter baumannii*: assessing their impact on organ transplantation. *Curr Opin Organ Transplant.* 2010 Dec;15(6):676-82. PubMed PMID: [20930636](#).
20. Ray A, **Perez F**, Beltrami AM, Jakubowycz M, Dimick P, et al. Use of vaporized hydrogen peroxide decontamination during an outbreak of multidrug-resistant *Acinetobacter baumannii* infection at a long-term acute care hospital. *Infect Control Hosp Epidemiol.* 2010 Dec;31(12):1236-41. PubMed PMID: [20973723](#); PubMed Central PMCID: [PMC3731999](#).
21. Marchaim D, Chopra T, Pogue JM, **Perez F**, Hujer AM, et al. Outbreak of colistin-resistant, carbapenem-resistant *Klebsiella pneumoniae* in metropolitan Detroit, Michigan. *Antimicrob Agents Chemother.* 2011 Feb;55(2):593-9. PubMed PMID: [21115786](#); PubMed Central PMCID: [PMC3028794](#).
22. **Perez F**, Ponce-Terashima R, Adams MD, Bonomo RA. Are we closing in on an "elusive enemy"? The current status of our battle with *Acinetobacter baumannii*. *Virulence.* 2011 Mar-Apr;2(2):86-90. PubMed PMID: [21499025](#).
23. **Perez F**, Pultz MJ, Endimiani A, Bonomo RA, Donskey CJ. Effect of antibiotic treatment on establishment and elimination of intestinal colonization by KPC-producing *Klebsiella pneumoniae* in mice. *Antimicrob Agents Chemother.* 2011 Jun;55(6):2585-9. PubMed PMID: [21422202](#); PubMed Central PMCID: [PMC3101444](#).
24. Marchaim D, Chopra T, **Perez F**, Hayakawa K, Lephart PR, et al. Outcomes and genetic relatedness of carbapenem-resistant *Enterobacteriaceae* at Detroit medical center. *Infect Control Hosp Epidemiol.* 2011 Sep;32(9):861-71. PubMed PMID: [21828966](#); PubMed Central PMCID: [PMC4067763](#).
25. Decker BK, **Perez F**, Hujer AM, Hujer KM, Hall GS, et al. Longitudinal analysis of the temporal evolution of *Acinetobacter baumannii* strains in Ohio, USA, by using rapid automated typing methods. *PLoS One.* 2012;7(4):e33443. PubMed PMID: [22511922](#); PubMed Central PMCID: [PMC3325217](#).
26. Viau RA, Hujer AM, Marshall SH, **Perez F**, Hujer KM, et al. "Silent" dissemination of *Klebsiella pneumoniae* isolates bearing *K. pneumoniae* carbapenemase in a long-term care facility for children and young adults in Northeast Ohio. *Clin Infect Dis.* 2012 May;54(9):1314-21. PubMed PMID: [22492318](#); PubMed Central PMCID: [PMC3404693](#).
27. Marchaim D, Chopra T, Bhargava A, Bogan C, Dhar S, Hayakawa K, Pogue JM, Bheemreddy S, Blunden C, Shango M, Swan J, Lephart PR, **Perez F**, Bonomo RA, Kaye KS. Recent exposure to antimicrobials and carbapenem-

- resistant Enterobacteriaceae: the role of antimicrobial stewardship. *Infect Control Hosp Epidemiol*. 2012 Aug;33(8):817-30. PubMed PMID: [22759550](#).
28. Marchaim D, **Perez F**, Lee J, Bheemreddy S, Hujer AM, et al. "Swimming in resistance": Co-colonization with carbapenem-resistant *Enterobacteriaceae* and *Acinetobacter baumannii* or *Pseudomonas aeruginosa*. *Am J Infect Control*. 2012 Nov;40(9):830-5. PubMed PMID: [22325727](#); PubMed Central PMCID: [PMC4030534](#).
 29. Drawz PE, **Perez F**, Bonomo RA. Acyclovir induced hypokalemia. *J Clin Virol*. 2013 Feb;56(2):177-8. PubMed PMID: [23122658](#); PubMed Central PMCID: [PMC4018808](#).
 30. **Perez F**, Van Duin D. Carbapenem-resistant *Enterobacteriaceae*: a menace to our most vulnerable patients. *Cleve Clin J Med*. 2013 Apr;80(4):225-33. PubMed PMID: [23547093](#); PubMed Central PMCID: [PMC3960994](#).
 31. **Perez F**, Rudin SD, Marshall SH, Coakley P, Chen L, et al. OqxAB, a quinolone and olaquinox efflux pump, is widely distributed among multidrug-resistant *Klebsiella pneumoniae* isolates of human origin. *Antimicrob Agents Chemother*. 2013 Sep;57(9):4602-3. PubMed PMID: [23817374](#); PubMed Central PMCID: [PMC3754307](#).
 32. Wright MS, Haft DH, Harkins DM, **Perez F**, Hujer KM, et al. New insights into dissemination and variation of the health care-associated pathogen *Acinetobacter baumannii* from genomic analysis. *MBio*. 2014 Jan 21;5(1):e00963-13. PubMed PMID: [24449752](#); PubMed Central PMCID: [PMC3903280](#).
 33. **Perez F**, Deshpande A, Kundrapu S, Hujer AM, Bonomo RA, et al. Pseudo-outbreak of *Klebsiella oxytoca* spontaneous bacterial peritonitis attributed to contamination of multidose vials of culture medium supplement. *Infect Control Hosp Epidemiol*. 2014 Feb;35(2):139-43. PubMed PMID: [24442075](#); PubMed Central PMCID: [PMC3957413](#).
 34. **Perez F**, Bonomo RA. Vaccines for *Acinetobacter baumannii*: thinking "out of the box". *Vaccine*. 2014 May 7;32(22):2537-9. PubMed PMID: [24662709](#); PubMed Central PMCID: [PMC4028134](#).
 35. Tugal D, Lynch M, Hujer AM, Rudin S, **Perez F**, et al. Multi-Drug-Resistant *Klebsiella pneumoniae* Pancreatitis: A New Challenge in a Serious Surgical Infection. *Surg Infect (Larchmt)*. 2014 May 21; PubMed PMID: [24850293](#).
 36. Bogan C, Kaye KS, Chopra T, Hayakawa K, Pogue JM, Lephart PR, Bheemreddy S, Lazarovitch T, Zaidenstein R, **Perez F**, Bonomo RA, Marchaim D. Outcomes of carbapenem-resistant *Enterobacteriaceae* isolation: matched analysis. *Am J Infect Control*. 2014 Jun;42(6):612-20. PubMed PMID: [24837111](#).
 37. Suwantarant N, Rudin SD, Marshall SH, Hujer AM, **Perez F**, et al. Infections caused by fluoroquinolone-resistant *Escherichia coli* following transrectal ultrasound-guided biopsy of the prostate. *J Glob Antimicrob Resist*. 2014 Jun 1;2(2):71-76. PubMed PMID: [25024933](#); PubMed Central PMCID: [PMC4093839](#).
 38. Ramirez MS, Xie G, Johnson S, Davenport K, van Duin D, **Perez F**, et al. Genome Sequences of Two Carbapenemase-Resistant *Klebsiella pneumoniae* ST258 Isolates. *Genome Announc*. 2014 Jun 19;2(3) PubMed PMID: [24948759](#); PubMed Central PMCID: [PMC4064024](#).
 39. van Duin D, **Perez F**, Rudin SD, Cober E, Hanrahan J, et al. Surveillance of carbapenem-resistant *Klebsiella pneumoniae*: tracking molecular epidemiology and outcomes through a regional network. *Antimicrob Agents Chemother*. 2014 Jul;58(7):4035-41. PubMed PMID: [24798270](#); PubMed Central PMCID: [PMC4068524](#).
I collaborated with the initial conformation and laboratory work carried out for CRACKLE, a network of hospitals to study microbiological determinants of clinical outcomes in patients with carbapenem-resistant K. pneumoniae, which has led to more than a dozen publications.
 40. de Sanctis J, Teixeira L, van Duin D, Odio C, Hall G, Tomford JW, **Perez F**, et al. Complex prosthetic joint infections due to carbapenemase-producing *Klebsiella pneumoniae*: a unique challenge in the era of untreatable infections. *Int J Infect Dis*. 2014 Aug;25:73-8. PubMed PMID: [24813874](#); PubMed Central PMCID: [PMC4336167](#).
 41. Wright MS, **Perez F**, Brinkac L, Jacobs MR, Kaye K, et al. Population structure of KPC-producing *Klebsiella pneumoniae* isolates from midwestern U.S. hospitals. *Antimicrob Agents Chemother*. 2014 Aug;58(8):4961-5. PubMed PMID: [24913165](#); PubMed Central PMCID: [PMC4136011](#).
 42. Kiedrowski LM, Guerrero DM, **Perez F**, Viau RA, Rojas LJ, et al. Carbapenem-resistant *Enterobacter cloacae* isolates producing KPC-3, North Dakota, USA. *Emerg Infect Dis*. 2014 Sep;20(9):1583-5. PubMed PMID: [25153967](#); PubMed Central PMCID: [PMC4178402](#).
 43. **Perez F**, Hujer AM, Marshall SH, Ray AJ, Rather PN, et al. Extensively drug-resistant *Pseudomonas aeruginosa* isolates containing *bla_{VIM-2}* and elements of *Salmonella* genomic island 2: a new genetic resistance determinant in Northeast Ohio. *Antimicrob Agents Chemother*. 2014 Oct;58(10):5929-35. PubMed PMID: [25070102](#); PubMed Central PMCID: [PMC4187935](#).
This report of an unusual yet highly impactful resistance genotype of Pseudomonas aeruginosa producing metallo-beta-lactamase in Northeast Ohio was featured in a press release from the American Society for Microbiology and by National Public Radio (<https://archive.wksu.org/news/feature/exploradio/40230>).

44. Perez F, Adachi J, Bonomo RA. Antibiotic-resistant gram-negative bacterial infections in patients with cancer. *Clin Infect Dis*. 2014 Nov 15;59 Suppl 5: S335-9. PubMed PMID: [25352627](#); PubMed Central PMCID: [PMC4303050](#).
45. van Duin D, Cober ED, Richter SS, **Perez F**, Cline M, et al. Tigecycline therapy for carbapenem-resistant *Klebsiella pneumoniae* (CRKP) bacteriuria leads to tigecycline resistance. *Clin Microbiol Infect*. 2014 Dec;20(12):O1117-20. PubMed PMID: [24931918](#); PubMed Central PMCID: [PMC4265572](#).
46. van Duin D, Cober E, Richter SS, **Perez F**, Kalayjian RC, et al. Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant *Klebsiella pneumoniae*. *J Antimicrob Chemother*. 2015 Apr;70(4):1203-11. PubMed PMID: [25492391](#).
47. Correa A, Del Campo R, Perenguez M, Blanco VM, Rodríguez-Baños M, **Perez F**, Maya JJ, Rojas L, Cantón R, Arias CA, Villegas MV. Dissemination of High-Risk Clones of Extensively Drug-Resistant *Pseudomonas aeruginosa* in Colombia. *Antimicrob Agents Chemother*. 2015 Apr;59(4):2421-5. PubMed PMID: 25605362.
48. Patel G, **Perez F**, Hujer AM, Rudin SD, Augustine JJ, et al. Fulminant endocarditis and disseminated infection caused by carbapenem-resistant *Acinetobacter baumannii* in a renal-pancreas transplant recipient. *Transpl Infect Dis*. 2015 Feb 6; PubMed PMID: 25661804.
49. **Perez F**, Villegas MV. The role of surveillance systems in confronting the global crisis of antibiotic-resistant bacteria. *Curr Opin Infect Dis*. 2015 Aug;28(4):375-83. PubMed PMID: 26098505.
50. Khatri A, Naeger Murphy N, Wiest P, Osborn M, Garber K, Hecker M, Hurless K, Rudin SD, Jacobs MR, Kalayjian RC, Salata RA, van Duin D, **Perez F**, Bonomo RA, Paterson DL, Harris PN. Community-Acquired Pyelonephritis in Pregnancy Caused by KPC-Producing *Klebsiella pneumoniae*. *Antimicrob Agents Chemother*. 2015 Aug;59(8):4375-8. doi: 10.1128/AAC.00553-15. PubMed PMID: 26185273; PubMed Central PMCID: PMC4505232.
51. Lazarovitch T, Amity K, Coyle JR, Ackerman B, Tal-Jasper R, Ofer-Friedman H, Hayakawa K, Bogan C, Lephart PR, Kaplansky T, Maskit M, Azouri T, Zaidenstein R, **Perez F**, Bonomo RA, Kaye KS, Marchaim D. The Complex Epidemiology of Carbapenem-Resistant *Enterobacter* Infections: A Multicenter Descriptive Analysis. *Infect Control Hosp Epidemiol*. 2015 Sep 24:1-9 PubMed PMID: 26399907
52. Viau R, Frank KM, Jacobs MR, Wilson B, Kaye K, Donskey CJ, **Perez F**, Endimiani A, Bonomo RA. Intestinal Carriage of Carbapenemase-Producing Organisms: Current Status of Surveillance Methods. *Clin Microbiol Rev*. 2016 Jan;29(1):1-27. PubMed PMID: 26511484
53. Messina JA, Cober E, Richter SS, **Perez F**, Salata RA, Kalayjian RC, Watkins RR, Scalera NM, Doi Y, Kaye KS, Evans S, Bonomo RA, Fowler VG, van Duin D. Hospital Readmissions in Patients with Carbapenem-Resistant *Klebsiella pneumoniae*. *Infect Control Hosp Epidemiol*. 2015 Dec 21:1-8. PubMed PMID: 26686227.
54. **Perez F**, Jump RL. New Developments in Adult Vaccination: Challenges and Opportunities to Protect Vulnerable Veterans from Pneumococcal Disease. *Federal Practitioner: for the health care professionals of the VA, DoD, and PHS*. 2015 December; 32(12):12-18.
55. Jump RL, Banks R, Wilson B, Montpetite MM, Carter R, Phillips S, **Perez F**. A Virtual Clinic Improves Pneumococcal Vaccination for Asplenic Veterans at High Risk for Pneumococcal Disease. *Open Forum Infect Dis*. 2015 Nov 3;2(4): ofv165. doi: 10.1093/ofid/ofv165. eCollection 2015 Dec. PubMed PMID: 26668815; PubMed Central PMCID: PMC4676800.
56. **Perez F**, El Chakhtoura NG, Papp-Wallace K, Wilson BM, Bonomo RA. Treatment Options for Infections Caused by Carbapenem-resistant Enterobacteriaceae: Can We Apply "Precision Medicine" to Antimicrobial Chemotherapy? *Expert Opin Pharmacother*. 2016 Jan 22. [Epub ahead of print] PubMed PMID: 26799840.
This review anticipated the future use of new agents to treat carbapenem-resistant Enterobacteria with prescient clarity, and has been very impactful with 150 citations according to Google Scholar.
57. Evans SR, Hujer AM, Jiang H, Hujer KM, Hall T, Marzan C, Jacobs MR, Sampath R, Ecker DJ, Manca C, Chavda K, Zhang P, Fernandez H, Chen L, Mediavilla JR, Hill, CB, **Perez F**, Caliendo AM, Fowler VG Jr, Chambers HF, Kreiswirth BN, Bonomo RA. Rapid Molecular Diagnostics, Antibiotic Treatment Decisions, and Developing Approaches to Inform Empiric Therapy: PRIMERS I and II. *Clin Infect Dis*. 2016 Jan 15;62(2):181-9. PubMed PMID: 26409063; PubMed Central PMCID: PMC4690483.
58. Dhar S, Martin ET, Lephart PR, McRoberts JP, Chopra T, Burger TT, Tal-Jasper, R, Hayakawa K, Ofer-Friedman H, Lazarovitch T, Zaidenstein R, **Perez F**, Bonomo RA, Kaye KS, Marchaim D.. Risk Factors and Outcomes for Carbapenem-Resistant *Klebsiella pneumoniae* Isolation, Stratified by Its Multilocus Sequence Typing: ST258 Versus Non-ST258. *Open Forum Infect Dis*. 2016 Feb 12;3(1): ofv213. PubMed PMID: 26885543; PubMed Central PMCID: PMC4751918.

59. Messina JA, Cober E, Richter SS, **Perez F**, Salata RA, et al. Hospital Readmissions in Patients With Carbapenem-Resistant *Klebsiella pneumoniae*. *Infect Control Hosp Epidemiol*. 2016 Mar;37(3):281-8. PubMed PMID: 26686227; NIHMSID: NIHMS749067; PubMed Central PMCID: PMC4785868.
60. Gutiérrez-Gutiérrez B, Pérez-Galera S, Salamanca E, de Cueto M, Calbo E, Almirante B, Viale P, Oliver A, Pintado V, Gasch O, Martínez-Martínez L, Pitout J, Akova M, Peña C, Molina J, Hernández A, Venditti M, Prim N, Origüen J, Bou G, Tacconelli E, Tumbarello M, Hamprecht A, Giamarellou H, Almela M, **Pérez F**, Schwaber MJ, Bermejo J, Lowman W, Hsueh PR, Mora-Rillo M, Natera C, Souli M, Bonomo RA, Carmeli Y, Paterson DL, Pascual A, Rodríguez-Baño J. Ertapenem for the treatment of bloodstream infections due to ESBL-producing *Enterobacteriaceae*: a multinational pre-registered cohort study. *J Antimicrob Chemother*. 2016 Jun;71(6):1672-80. PubMed PMID: 26907184; PubMed Central PMCID: PMC4867097.
61. Hauck C, Cober E, Richter SS, **Perez F**, Salata RA, et al. Spectrum of excess mortality due to carbapenem-resistant *Klebsiella pneumoniae* infections. *Clin Microbiol Infect*. 2016 Jun;22(6):513-9. PubMed PMID: 26850824; NIHMSID: NIHMS757047; PubMed Central PMCID: PMC4930369.
62. Gutiérrez-Gutiérrez B, Bonomo RA, Carmeli Y, Paterson DL, Almirante B, Martínez-Martínez L, Oliver A, Calbo E, Peña C, Akova M, Pitout J, Origüen J, Pintado V, García-Vázquez E, Gasch O, Hamprecht A, Prim N, Tumbarello M, Bou G, Viale P, Tacconelli E, Almela M, Pérez F, Giamarellou H, Cisneros JM, Schwaber MJ, Venditti M, Lowman W, Bermejo J, Hsueh PR, Mora-Rillo M, Gracia-Ahulfinger I, Pascual A, Rodríguez-Baño J; REIPI/ESGBIS/INCREMENT Group. A Multinational, Preregistered Cohort Study of β -Lactam/ β -Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum- β -Lactamase-Producing *Enterobacteriaceae*. *Antimicrob Agents Chemother*. 2016 Jul;60(7):4159-69. PubMed PMID: 27139473; PubMed Central PMCID: PMC4914653.
- I served as a collaborator by submitting cases to the INCREMENT Group, a multinational study led by Dr. Jesus Rodriguez-Baño that investigated bloodstream infections caused by extended-spectrum cephalosporin and carbapenem-resistant Enterobacteria. This collaboration resulted in 7 publications.*
63. Ramirez MS, Xie G, Traglia GM, Johnson SL, Davenport KW, van Duin D, Ramazani A, Perez F, Jacobs MR, Sherratt DJ, Bonomo RA, Chain PS, Tolmasky ME. Whole-Genome Comparative Analysis of Two Carbapenem-Resistant ST-258 *Klebsiella pneumoniae* Strains Isolated during a North-Eastern Ohio Outbreak: Differences within the High Heterogeneity Zones. *Genome Biol Evol*. 2016 Jul 3;8(6):2036-43. PubMed PMID: 27289094; PubMed Central PMCID: PMC4943203.
64. Mojica MF, Ouellette CP, Leber A, Becknell MB, Ardura MI, **Perez F**, Shimamura M, Bonomo RA, Aitken SL, Shelburne SA. Successful Treatment of Bloodstream Infection Due to Metallo- β -Lactamase-Producing *Stenotrophomonas maltophilia* in a Renal Transplant Patient. *Antimicrob Agents Chemother*. 2016 Sep;60(9):5130-4. PubMed PMID: 27551008; PubMed Central PMCID: PMC4997835.
65. Domitrovic TN, Hujer AM, **Perez F**, Marshall SH, Hujer KM, Woc-Colburn LE, Parta M, Bonomo RA. Multidrug Resistant *Pseudomonas aeruginosa* Causing Prosthetic Valve Endocarditis: A Genetic-Based Chronicle of Evolving Antibiotic Resistance. *Open Forum Infect Dis*. 2016 Oct 21;3(4). PubMed PMID: 29057280
66. Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, Hsueh PR, Viale P, Paño-Pardo JR, Venditti M, Tumbarello M, Daikos G, Pintado V, Doi Y, Tuon FF, Karaiskos I, Machuca I, Schwaber MJ, Azap ÖK, Souli M, Roilides E, Pournaras S, Akova M, **Pérez F**, Bermejo J, Oliver A, Almela M, Lowman W, Almirante B, Bonomo RA, Carmeli Y, Paterson DL, Pascual A, Rodríguez-Baño J; Investigators from the REIPI/ESGBIS/INCREMENT Group. A Predictive Model of Mortality in Patients with Bloodstream Infections due to Carbapenemase-Producing *Enterobacteriaceae*. *Mayo Clin Proc*. 2016 Oct;91(10):1362-1371. PubMed PMID: 27712635.
67. Rojas LJ, Salim M, Cober E, Richter SS, **Perez F**, Salata RA, Kalayjian RC, Watkins RR, Marshall S, Rudin SD, Domitrovic TN, Hujer AM, Hujer KM, Doi Y, Kaye KS, Evans S, Fowler VG Jr, Bonomo RA, van Duin D; Antibacterial Resistance Leadership Group. Colistin Resistance in Carbapenem-Resistant *Klebsiella pneumoniae*: Laboratory Detection and Impact on Mortality. *Clin Infect Dis*. 2016 Dec 10; PubMed PMID: 27940944. \
68. Palacios-Baena ZR, Gutiérrez-Gutiérrez B, De Cueto M, Viale P, Venditti M, Hernández-Torres A, Oliver A, Martínez-Martínez L, Calbo E, Pintado V, Gasch O, Almirante B, Antonio Lepe J, Pitout J, Akova M, Peña-Miralles C, Schwaber MJ, Tumbarello M, Tacconelli E, Origüen J, Prim N, Bou G, Giamarellou H, Bermejo J, Hamprecht A, **Pérez F**, Almela M, Lowman W, Hsueh PR, Navarro-San Francisco C, Torre-Cisneros J, Carmeli Y, Bonomo RA, Paterson DL, Pascual A, Rodríguez-Baño J; REIPI/ESGBIS/INCREMENT Group. Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum- β -lactamase-producing *Enterobacteriaceae*. *J Antimicrob Chemother*. 2017 Jan 6; PubMed PMID: 28062685.
69. Marshall S, Hujer AM, Rojas LJ, Papp-Wallace KM, Humphries RM, Spellberg B, Hujer KM, Marshall EK, Rudin SD, **Perez F**, Wilson BM, Wasserman RB, Chikowski L, Paterson DL, Vila AJ, van Duin D, Kreiswirth BN,

- Chambers HF, Fowler VG Jr, Jacobs MR, Pulse ME, Weiss WJ, Bonomo RA. Can ceftazidime/avibactam and aztreonam overcome β -lactam resistance conferred by metallo- β -lactamases in Enterobacteriaceae? *Antimicrob Agents Chemother*. 2017 Feb 6; PubMed PMID: 28167541
70. Wilson BM, El Chakhtoura NG, Patel S, Saade E, Donskey CJ, Bonomo RA, **Perez F**. Carbapenem-Resistant *Enterobacter cloacae* in Patients from the US Veterans Health Administration, 2006-2015. *Emerg Infect Dis*. 2017 May;23(5):878-880. PubMed PMID: 28418318.
 71. Viau RA, Kiedrowski LM, Kreiswirth BN, Adams M, **Perez F**, Marchaim D, Guerrero DM, Kaye KS, Logan LK, Villegas MV, Bonomo RA. A Comparison of Molecular Typing Methods Applied to *Enterobacter cloacae* complex: hsp60 Sequencing, Rep-PCR, and MLST. *Pathog Immun*. 2017;2(1):23-33.
 72. Marshall S, Hujer AM, Rojas LJ, Papp-Wallace KM, Humphries RM, Spellberg B, Hujer KM, Marshall EK, Rudin SD, **Perez F**, Wilson BM, Wasserman RB, Chikowski L, Paterson DL, Vila AJ, van Duin D, Kreiswirth BN, Chambers HF, Fowler VG Jr, Jacobs MR, Pulse ME, Weiss WJ, Bonomo RA. Can Ceftazidime-Avibactam and Aztreonam Overcome β -Lactam Resistance Conferred by Metallo- β -Lactamases in Enterobacteriaceae? *Antimicrob Agents Chemother*. 2017 Mar 24;61(4). PubMed PMID: 28167541; PubMed Central PMCID: PMC5365724.
 73. Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, Hsueh PR, Viale P, Paño-Pardo JR, Venditti M, Tumbarello M, Daikos G, Cantón R, Doi Y, Tuon FF, Karaiskos I, Pérez-Nadales E, Schwaber MJ, Azap ÖK, Souli M, Roilides E, Pournaras S, Akova M, **Pérez F**, Bermejo J, Oliver A, Almela M, Lowman W, Almirante B, Bonomo RA, Carmeli Y, Paterson DL, Pascual A, Rodríguez-Baño J; REIPI/ESGBIS/INCREMENT Investigators.. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. *Lancet Infect Dis*. 2017 Apr 21.
 74. Rojas LJ, Hujer AM, Rudin SD, Wright MS, Domitrovic TN, Marshall SH, Hujer KM, Richter SS, Cober E, **Perez F**, Adams MD, van Duin D, Bonomo RA; Antibacterial Resistance Leadership Group (ARLG). NDM-5 and OXA-181 beta-lactamases: a significant threat continues to spread in the Americas. *Antimicrob Agents Chemother*. 2017 May 1.
 75. Correa A, Del Campo R, Escandón-Vargas K, Perenguez M, Rodríguez-Baños M, Hernández-Gómez C, Pallares C, **Perez F**, Arias CA, Cantón R, Villegas MV. Distinct Genetic Diversity of Carbapenem-Resistant *Acinetobacter baumannii* from Colombian Hospitals. *Microb Drug Resist*. 2017 Jun 1. PubMed PMID: 28570118.
 76. Munita JM, Aitken SL, Miller WR, **Perez F**, Rosa R, Shimose LA, Lichtenberger PN, Abbo LM, Jain R, Nigo M, Wanger A, Araos R, Tran TT, Adachi J, Rakita R, Shelburne S, Bonomo RA, Arias CA. Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant *Pseudomonas aeruginosa*. *Clin Infect Dis*. 2017 Jul 1;65(1):158-161. PubMed PMID: 28329350.
 77. Henig O, Cober E, Richter SS, **Perez F**, Salata RA, Kalayjian RC, Watkins RR, Marshall S, Rudin SD, Domitrovic TN, Hujer AM, Hujer KM, Doi Y, Evans S, Fowler VG Jr, Bonomo RA, van Duin D, Kaye KS; Antibacterial Resistance Leadership Group. A Prospective Observational Study of the Epidemiology, Management, and Outcomes of Skin and Soft Tissue Infections Due to Carbapenem-Resistant Enterobacteriaceae. *Open Forum Infect Dis*. 2017 Jul 27;4(3):ofx157. PubMed PMID: 29026866; PubMed Central PMCID: PMC5629814.
 78. Harris PNA, Pezzani MD, Gutiérrez-Gutiérrez B, Viale P, Hsueh PR, Ruiz-Garbajosa P, Venditti M, Tumbarello M, Navarro-Francisco C, Calbo E, Akova M, Giamarellou H, Oliver A, Almirante B, Gasch O, Martínez-Martínez L, Schwaber MJ, Daikos G, Pitout J, Peña C, Hernández-Torres A, Doi Y, Pérez F, Tuon FF, Tacconelli E, Carmeli Y, Bonomo RA, Pascual Á, Paterson DL, Rodríguez-Baño J;ESGBIS/REIPI/INCREMENT Group. Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. *Int J Antimicrob Agents*. 2017 Aug 3
 79. Palacios-Baena ZR, Gutiérrez-Gutiérrez B, Calbo E, Almirante B, Viale P, Oliver A, Pintado V, Gasch O, Martínez-Martínez L, Pitout J, Akova M, Peña C, Molina Gil-Bermejo J, Hernández A, Venditti M, Prim N, Bou G, Tacconelli E, Tumbarello M, Hamprecht A, Giamarellou H, Almela M, **Pérez F**, Schwaber MJ, Bermejo J, Lowman W, Hsueh PR, Paño-Pardo JR, Torre-Cisneros J, Souli M, Bonomo RA, Carmeli Y, Paterson DL, Pascual Á, Rodríguez-Baño J; Spanish Network for Research in Infectious Diseases (REIPI)/European Study Group of Bloodstream Infections and Sepsis (ESGBIS)/INCREMENT Group. Empiric Therapy with Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β -Lactamase-Producing Enterobacteriaceae: Results from the INCREMENT Cohort. *Clin Infect Dis*. 2017 Aug 19. PubMed PMID: 29020250.
 80. Rosa R, Rudin SD, Rojas LJ, Perez-Cardona A, Aragon L, Nicolau DP, **Perez F**, Hujer AM, Tekin A, Martinez O, Camargo JF, Bonomo RA, Abbo LM. Application of "Precision Medicine" Through the Molecular Characterization of Extensively Drug-Resistant *Klebsiella pneumoniae* in a Multivisceral Transplant Patient. *Clin Infect Dis*. 2017 Aug 15;65(4):701-702. PubMed PMID:29017264.
 81. van Duin D, Lok JJ, Earley M, Cober E, Richter SS, **Perez F**, Salata RA, Kalayjian RC, Watkins RR, Doi Y, Kaye KS, Fowler VG Jr, Paterson DL, Bonomo RA, Evans S; Antibacterial Resistance Leadership Group. Colistin vs.

- Ceftazidime-avibactam in the Treatment of Infections due to Carbapenem-Resistant Enterobacteriaceae. *Clin Infect Dis*. 2017 Sep 4. PubMed PMID: 29020404.
82. Rojas LJ, Weinstock GM, De La Cadena E, Diaz L, Rios R, Hanson BM, Brown JS, Vats P, Phillips DS, Nguyen H, Hujer KM, Correa A, Adams MD, **Perez F**, Sodergren E, Narechania A, Planet PJ, Villegas MV, Bonomo RA, Arias CA. An Analysis of the Epidemic of KPC-Producing *Klebsiella pneumoniae*: Convergence of Two Evolutionary Mechanisms Creates the "Perfect Storm". *J Infect Dis*. 2017 Sep 27. PubMed PMID: 29029188.
 83. El Chakhtoura NG, Saade E, Wilson BM, **Perez F**, Papp-Wallace KM, Bonomo RA. A 17-Year Nationwide Study of *Burkholderia cepacia* Complex Bloodstream Infections Among Patients in the United States Veterans Health Administration. *Clin Infect Dis*. 2017 Oct 15;65(8):1253-1259. PubMed PMID: 29017247.
 84. Burns CM, Banks RE, Wilson BM, Carter RR, Jump RLP, **Perez F**. A virtual clinic improves pneumococcal vaccination coverage among patients living with HIV at a Veterans Affairs Medical Center. *AIDS Care*. 2017 Oct 20:1-4. PubMed PMID: 29052434.
 85. Rosa R, Rudin SD, Rojas LJ, Hujer AM, Perez-Cardona A, **Perez F**, Bonomo RA, Martínez O, Abbo LM, Camargo JF. "Double carbapenem" and oral fosfomycin for the treatment of complicated urinary tract infections caused by bla(NDM) -harboring Enterobacteriaceae in kidney transplantation. *Transpl Infect Dis*. 2017 Oct 24. PubMed PMID: 29064133.
 86. Eilertson B, Cober E, Richter SS, **Perez F**, Salata RA, Kalayjian RC, Watkins RR, Doi Y, Kaye KS, Evans S, Fowler VG Jr, Bonomo RA, DeHovitz J, Kreiswirth B, van Duin D; Antibacterial Resistance Leadership Group. Carbapenem-Resistant Enterobacteriaceae Infections in Patients on Renal Replacement Therapy. *Open Forum Infect Dis*. 2017 Oct 6;4(4): ofx216. PubMed PMID: 29181422
 87. De La Cadena E, Correa A, Muñoz JS, Rojas LJ, Hernández-Gómez C, Pallares C, **Perez F**, Bonomo RA, Villegas MV. Molecular characterization of carbapenem-resistant *Enterobacter cloacae* complex in Colombia: bla(KPC) and the "changing landscape". *J Glob Antimicrob Resist*. 2017 Dec 20. PubMed PMID: 29274468.
 88. El Chakhtoura NG, Saade E, Iovleva A, Yasmin M, Wilson B, **Perez F**, Bonomo RA. Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy. *Expert Rev Anti Infect Ther*. 2018 Feb;16(2):89-110. PubMed PMID: 29310479.
 89. Church EC, Banks R, Wilson B, Arfons L, **Perez F**, Jump R. Improving pneumococcal vaccine uptake in veterans with chronic lymphocytic leukemia through a virtual clinic. *Curr Oncol*. 2018 Feb;25(1): PubMed PMID: 29507501.
 90. Scheuerman O, Schechner V, Carmeli Y, Gutiérrez-Gutiérrez B, Calbo E, Almirante B, Viale PL, Oliver A, Ruiz-Garbajosa P, Gasch O, Gozalo M, Pitout J, Akova M, Peña C, Molina J, Hernández-Torres A, Venditti M, Prim N, Origüen J, Bou G, Tacconelli E, Tumbarello M, Hamprecht A, Karaiskos I, de la Calle C, **Pérez F**, Schwaber MJ, Bermejo J, Lowman W, Hsueh PR, Navarro-San Francisco C, Bonomo RA, Paterson DL, Pascual A, Rodríguez-Baño J; REIPI/ESGBIS/INCREMENT investigators. Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing *Escherichia coli* and ESBL-Producing *Klebsiella pneumoniae*. *Infect Control Hosp Epidemiol*. 2018 Apr 5:1-8. PubMed PMID: 29618394.
 91. Evans SR, Tran TTT, Hujer AM, Hill CB, Hujer KM, Mediavilla JR, Manca C, Domitrovic TN, **Perez F**, Farmer M, Pitzer KM, Wilson BM, Kreiswirth BN, Patel R, Jacobs MR, Chen L, Fowler VG Jr, Chambers HF, Bonomo RA; Antibacterial Resistance Leadership Group (ARLG). Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam against *Pseudomonas aeruginosa*: PRIMERS IV. *Clin Infect Dis*. 2018 Sep 20. PMID: 30239599.
 92. Chopra T, Rivard C, Awali RA, Krishna A, Bonomo RA, **Perez F**, Kaye KS. Epidemiology of Carbapenem-Resistant Enterobacteriaceae at a Long-term Acute Care Hospital. *Open Forum Infect Dis*. 2018 Oct 3;5(10). PMID: 30302351.
 93. Martinez J, Liu C, Rodman N, Fernandez JS, Barberis C, Sieira R, **Perez F**, Bonomo RA, Ramirez MS. Human fluids alter DNA-acquisition in *Acinetobacter baumannii*. *Diagn Microbiol Infect Dis*. 2019 Mar;93(3):183-187. doi: 10.1016/j.diagmicrobio.2018.10.010. Epub 2018 Oct 23. PubMed PMID: 30420211; PubMed Central PMCID: PMC6372348.
 94. Traglia GM, Place K, Dotto C, Fernandez JS, Montaña S, Bahiense CDS, Soler-Bistue A, Iriarte A, **Perez F**, Tolmasky ME, Bonomo RA, Melano RG, Ramírez MS. Interspecies DNA acquisition by a naturally competent *Acinetobacter baumannii* strain. *Int J Antimicrob Agents*. 2019 Apr;53(4):483-490. doi:10.1016/j.ijantimicag.2018.12.013. Epub 2019 Jan 3. PubMed PMID: 30611868; PubMed Central PMCID: PMC6456398.
 95. **Perez F**, El Chakhtoura NG, Yasmin M, Bonomo RA. Polymyxins: To Combine or Not to Combine? *Antibiotics (Basel)*. 2019 Apr 10;8(2). pii: E38. doi:10.3390/antibiotics8020038. Review. PubMed PMID: 30974813.

96. Bartley PS, Domitrovic TN, Moretto VT, Santos CS, Ponce-Terashima R, Reis MG, Barbosa LM, Blanton RE, Bonomo RA, **Perez F**. Antibiotic Resistance in Enterobacteriaceae from Surface Waters in Urban Brazil Highlights the Risks of Poor Sanitation. *Am J Trop Med Hyg*. 2019 Apr 15. doi: 10.4269/ajtmh.18-0726. [Epub ahead of print] PubMed PMID: 30994094.
- This project was undertaken in collaboration with Dr. Ronald Blanton, then at CWRU's Center for Global Health, and revealed that surface waters in our urban site in Brazil are a reservoir of resistance determinants thus illustrating the concept of One Health in antibiotic resistance.*
97. Dousa KM, De la Hoz A, Church E, Onger T, **Perez F**, Saade E. Progressive and disseminated histoplasma infection and hemophagocytic lymphohistiocytosis in an immunocompetent adult. *Clin Case Rep*. 2019 Mar 27;7(5):913-916. doi: 10.1002/ccr3.2079. PubMed PMID: 31110713
98. Pogue JM, Kaye KS, Veve MP, Patel TS, Gerlach AT, Davis SL, Puzniak LA, File TM, Olson S, Dhar S, Bonomo RA, **Perez F**. Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant *Pseudomonas aeruginosa*. *Clin Infect Dis*. 2019 Sep 23. pii: ciz816. doi: 10.1093/cid/ciz816. [Epub ahead of print] PubMed PMID: 31545346
- This multicentric case-control study conducted with Dr. Jason Pogue and Dr. Keith Kay found that ceftolozane/tazobactam was associated better clinical outcomes than aminoglycoside or colistin-based regimens for the treatment of multidrug resistant Pseudomonas aeruginosa, an observation that is captured in current treatment guidelines.*
99. Rodríguez-Núñez O, Periañez-Parraga L, Oliver A, Munita JM, Boté A, Gasch O, Nuvials X, Dinh A, Shaw R, Lomas JM, Torres V, Castón J, Araos R, Abbo LM, Rakita R, **Perez F**, Aitken SL, Arias CA, Martín-Pena ML, Colomar A, Núñez MB, Mensa J, Martínez JA, Soriano A. Higher MICs (>2 mg/L) Predict 30-Day Mortality in Patients With Lower Respiratory Tract Infections Caused by Multidrug- and Extensively Drug-Resistant *Pseudomonas aeruginosa* Treated With Ceftolozane/Tazobactam. *Open Forum Infect Dis*. 2019 Sep 28;6(10):ofz416. doi: 10.1093/ofid/ofz416. eCollection 2019 Oct. PubMed PMID: 31660373; PubMed Central PMCID: PMC6810667.
100. Wilson BM, Bessesen MT, Doros G, Brown ST, Saade E, Hermos J, **Perez F**, Skalweit M, Spellberg B, Bonomo RA. Adjunctive Rifampin Therapy For Diabetic Foot Osteomyelitis in the Veterans Health Administration. *JAMA Netw Open*. 2019 Nov 1;2(11):e1916003. doi: 10.1001/jamanetworkopen.2019.16003. PubMed PMID: 31755948; PubMed Central PMCID: PMC6902814.
101. Jump RLP, Wilson BM, Baechle D, Briggs JM, Banks RE, Song S, Zappernick T, **Perez F**. Risk Factors and Mortality Rates Associated With Invasive Group B Streptococcus Infections Among Patients in the US Veterans Health Administration. *JAMA Netw Open*. 2019 Dec 2;2(12):e1918324. doi:10.1001/jamanetworkopen.2019.18324. PubMed PMID: 31880800; PubMed Central PMCID: PMC6991221.
- We identified poor glycemic control as a risk factor for invasive infections caused by Group B Streptococcus (GBS) among veterans. In subsequent work we establish the substantial burden of non-invasive GBS infections. Together, these data may help inform preventive measures and immunization policies to protect veterans from GBS.*
102. Yasmin M, Fouts DE, Jacobs MR, Haydar H, Marshall SH, White R, D'Souza R, Lodise TP, Rhoads DD, Hujer AM, Rojas LJ, Hoyer C, Perez F, Edwards A, Bonomo RA. Monitoring Ceftazidime-Avibactam (CAZ-AVI) and Aztreonam (ATM) Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying both KPC-4 and NDM-1 Carbapenemases. *Clin Infect Dis*. 2019 Dec 5. pii: ciz1155. doi: 10.1093/cid/ciz1155. [Epub ahead of print] PubMed PMID: 31802119.
103. **Perez F**, Bonomo RA. Precision Medicine and Mysteries in Clinical Microbiology: Rationalizing Epidemiology, Genotype, and Phenotype To Guide Therapeutics. *Antimicrob Agents Chemother*. 2020 Jan 27;64(2). pii: e02264-19. doi: 10.1128/AAC.02264-19. Print 2020 Jan 27. PubMed PMID: 31740555; PubMed Central PMCID: PMC6985733.
104. Banks R, Zappernick T, Wilson B, **Perez F**, Jump RLP. A positive pneumococcal urinary antigen test promotes narrow spectrum antibiotic use in patients with non-invasive pneumococcal pneumonia. *Diagn Microbiol Infect Dis*. 2020 Feb;96(2):114897. doi: 10.1016/j.diagmicrobio.2019.114897. Epub 2019 Oct 5. PubMed PMID: 31740170.
105. Melia MT, Paez A, Reid G, Chirch LM, Luther VP, Blackburn BG, **Perez F**, Abdoler E, Kaul DR, Rehm S, Harik N, Barsoumian A, Person AK, Yun H, Beckham JD, Boruchoff S, Cariello PF, Cutrell JB, Graber CJ, Lee DH, Maziarz E, Paras ML, Razonable RR, Ressler R, Chen A, Chow B, Escota G, Herc E, Johnson A, Maves RC, Nnedu O, Clauss H, Kulkarni P, Pottinger PS, Serpa JA, Bhowmick T, Bittner M, Wooten D, Casanas B, Shnekendorf R, Blumberg EA. The Struggling Infectious Diseases Fellow: Remediation Challenges and Opportunities. *Open Forum Infect Dis*. 2020 Feb 18;7(3):ofaa058. doi: 10.1093/ofid/ofaa058. eCollection 2020 Mar. Review. PubMed PMID: 32166097

106. Davey CH, Weibel AR, Sehgal AR, Voss JG, Hsiao CP, Darrah R, Litman P, **Perez F**, Desai NB. Genetic Correlates of Fatigue in Individuals with End Stage Renal Disease. *West J Nurs Res*. 2020 Dec;42(12):1042-1049. doi: 10.1177/0193945920919911. Epub 2020 May 20. PMID: 32431239
107. Goldberg JA, Nguyen H, Kumar V, Spencer EJ, Hoyer D, Marshall EK, Cmolik A, O'Shea M, Marshall SH, Hujer AM, Hujer KM, Rudin SD, Domitrovic TN, Bethel CR, Papp-Wallace KM, Logan LK, **Perez F**, Jacobs MR, van Duin D, Kreiswirth BM, Bonomo RA, Plummer MS, van den Akker F. A γ -Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli. *J Med Chem*. 2020 Jun 11;63(11):5990-6002. doi: 10.1021/acs.jmedchem.0c00255. Epub 2020 Jun 2. PMID:32420736
108. Yasmin M, Hanrahan J, Marshall S, Lodise TP, Chen L, **Perez F**, Kreiswirth B, Bonomo RA. Using Therapeutic Drug Monitoring to Treat KPC-Producing *Klebsiella pneumoniae* Central Nervous System Infection With Ceftazidime/Avibactam. *Open Forum Infect Dis*. 2020 Aug 18;7(9):ofaa349. doi:10.1093/ofid/ofaa349. PMID: 32964066; PMCID: PMC7491706.
109. Wilson BM, Jiang Y, Jump RLP, Colindres RV, **Perez F**, Bonomo RA, Evans SR. Desirability of Outcome Ranking for the Management of Antimicrobial Therapy (DOOR MAT): A Framework for Assessing Antibiotic Selection Strategies in the Presence of Drug Resistance. *Clin Infect Dis*. 2020 Nov 27:ciaa1769. doi: 10.1093/cid/ciaa1769. Epub ahead of print. PMID: 33245333.
110. Horstman MJ, Miltner RS, Wallhagen MI, Patrician PA, Oliver BJ, Roumie CL, Dolansky MA, **Perez F**, Naik AD, Godwin KM. Developing Leaders and Scholars in Health Care Improvement: The VA Quality Scholars Program Competencies. *Acad Med*. 2021 Jan 1;96(1):68-74. doi: 10.1097/ACM.0000000000003658. PMID: 32769476.
111. Goldberg JA, Kumar V, Spencer EJ, Hoyer D, Marshall SH, Hujer AM, Hujer KM, Bethel CR, Papp-Wallace KM, **Perez F**, Jacobs MR, van Duin D, Kreiswirth BN, van den Akker F, Plummer MS, Bonomo RA. A γ -lactam siderophore antibiotic effective against multidrug-resistant *Pseudomonas aeruginosa*, *Klebsiella pneumoniae*, and *Acinetobacter* spp. *Eur J Med Chem*. 2021 Aug 5;220:113436. doi: 10.1016/j.ejmech.2021.113436. Epub 2021 Apr 8. PMID: 33933754.
112. **Perez F**, Colindres RV, Wilson BM, Saade E, Jump RLP, Banerjee R, Patel R, Evans SR, Bonomo RA. The Desirability of Outcome Ranking for the Management of Antimicrobial Therapy (DOOR MAT) Reveals Improvements in the Treatment of Bloodstream Infection Caused by *Escherichia coli* and *Klebsiella pneumoniae* in Patients from the Veterans Health Administration. *Clin Infect Dis*. 2021 May 12:ciab384. doi: 10.1093/cid/ciab384. Epub ahead of print. PMID: 33978146.
- This work demonstrated sustained reductions in antibiotic overtreatment without a negative impact on survival using DOOR MAT, a framework to assess the desirability of antibiotic treatment. This powerful tool can help evaluate the impact of system-wide antibiotic stewardship policies.*
113. Bej TA, Christian RL, Sims SV, Wilson BM, Song S, Akpoji UC, Bonomo RA, **Perez F**, Jump RLP. Influence of microbiological culture results on antibiotic choices for veterans with hospital-acquired pneumonia and ventilator-associated pneumonia. *Infect Control Hosp Epidemiol*. 2021 Jun 4:1-8. doi: 10.1017/ice.2021.186. Epub ahead of print. PMID: 34085618.
114. Le C, Pimentel C, Tuttobene MR, Subils T, Nishimura B, Traglia GM, **Perez F**, Papp-Wallace KM, Bonomo RA, Tolmasky ME, Ramirez MS. Interplay between meropenem and human serum albumin on expression of carbapenem resistance genes and natural competence in *Acinetobacter baumannii*. *Antimicrob Agents Chemother*. 2021 Jul 19:AAC0101921. doi: 10.1128/AAC.01019-21. Epub ahead of print. PMID: 34280015.
115. Bej T, Kothadia S, Wilson BM, Song S, Briggs JM, Banks RE, Donskey CJ, **Perez F**, Jump RLP. Impact of fever thresholds in detection of COVID-19 in Department of Veterans Affairs Community Living Center residents. *J Am Geriatr Soc*. 2021 Aug 10:10.1111/jgs.17415. doi: 10.1111/jgs.17415. Epub ahead of print. PMID: 34375443; PMCID: PMC8447344.
116. Camacho-Cordovez F, Kristi Henzel M, Bauer L, Chakhtoura NGE, Leili K, **Perez F**, Vida-Clough JA, Klonowski B, Kiefer P, Donskey C, Navas M. Bacterial Urine Profile and Optimal Urine Specimen Collection Timing in Asymptomatic Chronically Catheterized Adults with Spinal Cord Injuries and Disorders. *Am J Infect Control*. 2021 Sep 17:S0196-6553(21)00594-0. doi: 10.1016/j.ajic.2021.09.007. Epub ahead of print. PMID: 34543709.
117. Banks R, Wilson BM, Bej T, Briggs JM, Song S, Goto M, Jump RLP, **Perez F**. Similar Mortality among United States Veterans with Invasive and Non-Invasive Pneumonia due to Group B Streptococcus. *Open Forum Infectious Diseases*. Volume 9, Issue 3, March 2022, ofac051, <https://doi.org/10.1093/ofid/ofac051>. PMID: 35198653.
118. Chensupanimit T, Bej T, Wilson B, Banks RE, Song S, Briggs JM, Jump RLP, **Perez F**. Expanding the Definition Beyond Surveillance Criteria Reveals a Large Burden of Osteomyelitis caused by Group B Streptococcus in the United States Veterans Health Administration. *BMC Infect Dis*. 2022 Mar 8;22(1):237. doi: 10.1186/s12879-022-07238-0. PMID: 35260097.

119. Rojas LJ, Yasmin M, Benjamino J, Marshall SM, DeRonde KJ, Krishnan NP, **Perez F**, Colin AA, Cardenas M, Martinez O, Pérez-Cardona A, Rhoads DD, Jacobs MR, LiPuma JJ, Konstan MW, Vila AJ, Smania A, Mack AR, Scott JG, Adams MD, Abbo LM, Bonomo RA. Genomic heterogeneity underlies multidrug resistance in *Pseudomonas aeruginosa*: A population-level analysis beyond susceptibility testing. *PLoS One*. 2022 Mar 31;17(3):e0265129. doi: 10.1371/journal.pone.0265129. PMID: 35358221.
120. Shrestha R, Luterbach CL, Dai W, Komarow L, Earley M, Weston G, Herc E, Jacob JT, Salata R, Wong D, Anderson D, Rydell KB, Arias CA, Chen L, van Duin D; MDRO Investigators. Characteristics of community-acquired carbapenem-resistant Enterobacterales. *J Antimicrob Chemother*. 2022 Sep 30;77(10):2763-2771.
121. Mongilardi N, Wilson BM, Bej TA, Briggs JM, Banks RE, Song S, Jump RLP, **Perez F**. Group B Streptococcus in the urine in nonpregnant adults: Disease or distraction? *Antimicrob Steward Healthc Epidemiol*. 2022 Aug 4; 2 (1): e131. doi: 10.1017/ ash.2022.236. PMID: 36483389.
122. Akpoji UC, Wilson BM, Briggs JM, Song S, Bej TA, **Perez F**, Jump RLP. Antibiotic exposure and acquisition of antibiotic-resistant gram-negative bacteria among outpatients at a US Veterans Affairs medical center. *Antimicrob Steward Healthc Epidemiol*. 2022 Jan 12;2(1):e5.
123. Alabdely MH, Kothadia S, Bej T, Wilson BM, Song S, Akpoji U, Kowal C, **Perez F**, Jump RLP. Neither Race nor Ethnicity Impact the Mortality of Residents of Veterans Affairs Community Living Center With COVID-19. *J Am Med Dir Assoc*. 2023 Jan;24(1):22-26.e1. doi: 10.1016/j.jamda.2022.10.020. Epub 2022 Nov 4. PMID: 36462546.
124. Jump RLP, Mongilardi N, Wilson BM, Bej TA, Song S, Kowal CM, **Perez F**, Akpoji UC. Low rates of antibiotics prescribed during telehealth primary-care visits persisted during the coronavirus disease 2019 (COVID-19) pandemic. *Infect Control Hosp Epidemiol*. 2023 Feb 10:1-4. doi: 10.1017/ice.2022.309. PMID: 36762817.

Editorials & Letters

125. **Perez F**, Bonomo RA. Can we really use β -lactam/ β -lactam inhibitor combinations for the treatment of infections caused by extended-spectrum β -lactamase-producing bacteria? *Clin Infect Dis*. 2012 Jan 15;54(2):175-7. PubMed PMID: 22057699.
126. **Perez F**, Arias CA, Bush K, Drusano GL, Lolans K, et al. In memoriam: John P. Quinn, MD. *Clin Infect Dis*. 2014 Mar;58(5):748-50. PubMed PMID: 24336826; PubMed Central PMCID: PMC3934997.
127. **Perez F**, Bonomo RA. Bloodstream Infection Caused by Extended-Spectrum β -Lactamase-Producing Gram-Negative Bacteria: How to Define the Best Treatment Regimen? *Clin Infect Dis*. 2015 Jan 13; PubMed PMID: 25586684.
128. Evans S, Kreiswirth B, Fowler V, Chambers H, Patel R, Hujer AM, **Perez F**, Bonomo RA. Reply to Lesho and Clifford. *Clin Infect Dis*. 2016 May 25. PubMed PMID: 27225238.
129. **Perez F**, Bonomo RA. Evidence to improve the treatment of infections caused by carbapenem-resistant Gram-negative bacteria. *Lancet Infect Dis*. 2018 Apr;18(4):358-360. PubMed PMID: 29456042.
130. **Perez F**, Bonomo RA. Cardiac Devices Enveloped with an Ounce of Prevention. *N Engl J Med*. 2019 May 16;380(20):1965-1966. doi: 10.1056/NEJMe1905678. PubMed PMID: 31091379.
131. **Perez F**, Bonomo RA. Carbapenem-resistant Enterobacteriaceae: global action required. *Lancet Infect Dis*. 2019 Jun;19(6):561-562. doi:10.1016/S1473-3099(19)30210-5. Epub 2019 Apr 29. PubMed PMID: 31047851.
132. Wilson BM, **Perez F**, Pan Q, Jiang Y, Evans S, Bonomo RA. Acinetobacter infections. *Clin Infect Dis*. 2019 Nov 17. pii: ciz1099. doi: 10.1093/cid/ciz1099.[Epub ahead of print] PubMed PMID: 31734703.
133. Pogue JM, Kaye KS, Bonomo RA, **Perez F**. Reply to Vena, et al. *Clin Infect Dis*. 2020 Jan 6. pii: ciaa004. doi: 10.1093/cid/ciaa004. [Epub ahead of print] PubMed PMID: 31904808.
134. **Perez F**, Bonomo RA. Colistin resistance in China: from outer membrane to One Health. *Lancet Infect Dis*. 2020 Oct;20(10):1106-1108. doi:10.1016/S1473-3099(20)30242-5. Epub 2020 Jun 4. PMID: 32505233.
135. **Perez F**, Stiefel U. The Impact of Natural Transformation on the Acquisition of Antibiotic Resistance Determinants. *mBio*. 2022 May 12:e0033622. doi: 10.1128/mbio.00336-22. Epub ahead of print. PMID: 35548953.

Book Chapters

1. **Perez, F**, Bonomo, R.A. Acinetobacter. *Antimicrobial Drug Resistance*. Editors: Mayers, D.L., Sobel, J.D., Ouellette, M., Kaye, K.S., Marchaim, 2017.

Abstracts

1. Ray, A.; **Perez, F**.; Jakubowycz, M.; Dimick, P.; Jacobs, M. R.; Roman, K.; Bonomo, R.A.; Salata, R. A. The Use of Vaporized Hydrogen Peroxide Room Decontamination During an Outbreak of *Acinetobacter baumannii* at a Long-Term Acute Care Hospital. Abstract K-4124a presented at: The 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 25-28, 2008; Washington, DC

2. **Perez, F.**; Endimiani, A.; Hujer, A.; Bajaksouszian, S.; Good, C.; Jacobs, M. R.; Salata, R. A.; Bonomo, R. A. Outbreak of Carbapenem-Resistant *Klebsiella pneumoniae* Producing KPC-beta-lactamases Across a Hospital System in Northeast Ohio. Abstract K-1446 presented at: The 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 25-28, 2008; Washington, DC
3. **Perez, F.**; Ray, A.; Decker, B.; Hujer, A.; Higaki, L.; Good, C.; Jacobs, M. R.; Kunkel, P.; Bonomo, R. A.; Salata, R. A. Outbreak of Multi-Drug Resistant (MDR) *Acinetobacter baumannii* Across a Hospital System Originating in a Long-Term Care Facility. Abstract K-1454 presented at: The 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 25-28, 2008; Washington, DC.
4. Endimiani, A.; **Perez, F.**; Hujer, A. M.; Freedman, R. A.; Casiano-Colon, A. E.; Tenover, F. C.; Bonomo, R. A. Emergence of blaKPC-Containing *Klebsiella pneumoniae* Isolates in a Long-Term Acute Care Facility (LTACF) in South Florida. Abstract C2-3272 presented at: The 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 25-28, 2008; Washington, DC
5. Endimiani, A.; Bajaksouszian, S.; Windau, A.; **Perez, F.**; Choudhary, Y.; Bonomo, R. A.; Jacobs, M. R. Evaluation of the 2009 CLSI criteria for determining carbapenem susceptibility of *Klebsiella pneumoniae*. Abstract D-722 presented at: The 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2009; San Francisco, CA
6. **Perez, F.**; Pultz, M. J.; Endimiani, A.; Bonomo, R. A.; Donskey, C. J. Effect of antibiotic treatment on establishment of intestinal colonization by *Klebsiella pneumoniae* carbapenemase-producing *Klebsiella pneumoniae* in mice. Abstract B-1331 presented at: The 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2009; San Francisco, CA.
7. Decker, B.; **Perez, F.**; Ecker, D. J.; Bonomo, R. A. Understanding the molecular epidemiology of *Acinetobacter baumannii* in Ohio: a comparison of typing methods. Abstract C2-594 presented at: The 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2010; Boston, MA.
8. Marchaim, D.; **Perez, F.**; Hayakawa, K.; Hujer, K. M.; Lephart, P. R.; Bheemreddy, S.; Blunden, C.; Hujer, A. M.; Rudin, S.; Endimiani, A.; Bonomo, R. A.; Shango, M.; Slim, J.; Campbell, M.; Varkey, J.; Chen, T. Y.; Hothi, J. P.; Pogue, J. M.; Boikov, D.; Salimina, H.; Chopra, T.; Zhao, J. J.; Dhar, S.; Kaye, K. S. Outcomes and genetic relatedness of carbapenem-resistant Enterobacteriaceae at Detroit Medical Center. Abstract K-245 presented at: The 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2010; Boston, MA.
9. Adams, M. D.; **Perez, F.**; Molyneaux, N.; Bonomo, R. A. Extensive variability among contemporaneous isolates of *Acinetobacter baumannii*: insights from Genome Sequencing. Abstract C1-1954 presented at: The 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2010; Boston, MA.
10. Marchaim, D.; Bhargava, A.; Bogan, C.; Tankse, R.; Abreu-Lafranco, O.; Lephart, P. R.; Pogue, J. M.; Chopra, T.; Hayakawa, K.; Sunkara, B.; Dhar, S.; **Perez, F.**; Bonomo, R. A.; Kaye, K. S. Early dissemination of *Klebsiella pneumoniae* strains bearing KPC-beta-lactamase in a pediatric long-term care facility. Abstract K-819 presented at: The 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2011; Chicago, IL.
11. Viau, R. A.; Marshall, S. H.; Hujer, A. M.; **Perez, F.**; Bicero, D.; Bajaksouszian, S.; Jacobs, M. R.; Dul, M.; Grossbert, R.; Bonomo, R. A. Early dissemination of *Klebsiella pneumoniae* strains bearing KPC-beta-lactamase in a pediatric long-term care facility. Abstract C2-662 presented at: The 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2011; Chicago, IL.
12. **Perez, F.**; Bonomo, R. A.; Donskey, C. J. Pseudooutbreak of *Klebsiella oxytoca* spontaneous bacterial peritonitis attributed to contamination of multidose vials of culture medium supplement. Abstract K-234 presented at: The 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2011; Chicago, IL.
13. Adams, M. D.; **Perez, F.**; Hujer, K. M.; Jacobs, M. R.; Bonomo, R. A. A plasmid encoding the armA 23S rRNA methyltransferase gene isolated from *Acinetobacter baumannii* isolates in Cleveland. Abstract C1-367 presented at: The 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2011; Chicago, IL.
14. Abreu-Lanfranco, O.; Marchaim, D.; van Duin, D.; **Perez, F.**; Marshall, S. H.; Hayakawa, K.; Lephart, P.; Hall, G.; Jacobs, M.; Bonomo, R. A.; Kaye, K. S. A multicenter study of the epidemiology of colistin and carbapenem resistant *Klebsiella pneumoniae*; a preponderance of ST-258. Abstract 208 presented at: The 49th Annual Meeting of the Infectious Diseases Society of America, October 20-23, 2011; Boston, MA.
15. **Perez, F.**; Marshall, S. H.; Chen, L.; Coakley, P.; Kreiswirth, B. N.; van Duin, D.; Paterson, D. L.; Bonomo, R. A. OqxAB, a quinolone and olaquinox efflux pump is widely distributed among MDR *Klebsiella pneumoniae* of Human Origin in the Northeast USA. Abstract C2-692 presented at: The 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 9-12, 2012; San Francisco, CA.

16. Ruiz, S.; **Perez, F.**; Rudin, S. D.; Marshall, S. H.; Bajaksouszian, S.; Villegas, M.V.; Bonomo, R.A.; Jabocs, M. R. Dissemination of Diverse plasmids bearing blaKPC among carbapenem-resistant Enterobacteriaceae different from Klebsiella spp. in a Hospital System in Cleveland. Abstract C2-092 presented at: The 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 9-12, 2012; San Francisco, CA.
17. **Perez, F.**; Ray, A. J.; Dumford, D. M. III; Jacobs, M. R.; Bonomo, R. A. Metallo-beta-lactamases in the Heartland of the United States: International Strain of VIM-2 producing Pseudomonas aeruginosa in a community hospital in Northeast Ohio. Abstract C2-720 presented at: The 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 9-12, 2012; San Francisco, CA.
18. **Perez, F.**; Hanrahan, J.; Rudin, S.; Kalayjian, R.; Bonomo, R. A. Mapping the genetic lineages of Acinetobacter baumannii at a metropolitan academic hospital in Northeast Ohio; a 15-year comparison. Abstract 1425 presented at: IDWeek 2012; October 17-21, 2012; San Diego, CA.
19. Van Duin, D.; **Perez, F.**; Hanrahan, J.; Cober, E.; Cline, M.; Webber, R.; Ziegler, J.; Crowe, D.; Hall, G. S.; Jacobs, M. R.; Kalayjian, R.; Salata, R. A.; Bonomo, R. A. Molecular and clinical correlation in carbapenem-resistant Klebsiella pneumoniae: establishment of a surveillance network in Northeast Ohio (NeOSun). Abstract 1400 presented at: IDWeek 2012; October 17-21, 2012; San Diego, CA.
20. **Perez, F.** Insights into the evolving impact of multidrug resistant organisms through the integration of molecular and epidemiologic approaches. Abstract P34 presented at: The Translational Science Meeting, April 17-19, 2013; Washington, DC.
21. Adams, M. D.; Wright, M.; Brinkac, L.; J. McCarrison, S; Durkin, S; **Perez, F.**; et al. Association of KPC Variants with Clinical and Genomic Features in Klebsiella pneumoniae. Abstract C2-1444 presented at: The 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 10-13, 2013; Denver, CO.
22. Kiedrowski, L. M.; **Perez, F.**; Mojica, M. F.; et al. Carbapenem-resistant Enterobacter cloacae Outbreak in a North Dakota Healthcare Facility: Link to Long Term Acute Care (LTAC) Facilities and Co-colonization with Multidrug Resistant Organisms. Abstract K-697 presented at: The 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 10-13, 2013; Denver, CO.
23. Domitrovic, T. N.; Hujer, A. M.; **Perez, F.**; Marshall, S. H.; Hujer, K. M.; Woc-Colburn, L.; Parta, M.; Bonomo, R. A. Multidrug resistant Pseudomonas aeruginosa causing prosthetic valve endocarditis: a link between resistance and virulence. Abstract 276 presented at: IDWeek 2013; October 2-6, 2013; San Francisco, CA
24. Van Duin, D.; Cober, E.; **Perez, F.**; Kaye, K.; Gordon, S.; Kalayjian, R.; Salata, R. A.; Bonomo, R. A. Risk for readmissions in hospitalized patients with carbapenem-resistant Klebsiella pneumoniae. Abstract 1610 presented at: IDWeek 2013; October 2-6, 2013; San Francisco, CA.
25. Awali, R.; Biedron, C.; Imran, U.; Jegede, O.; Kaur, H.; Krishnan, B. G.; Datla, S.; Boikov, D.; Lebar, W.; Bonomo, R. A.; **Perez, F.**; Kaye, K. S.; Chopra, T. How fast do patients acquire Klebsiella pneumoniae containing blaKPC? An analysis of the epidemiology of Kp KPC at a long-term acute care facility. Abstract 1614 presented at: IDWeek 2013; October 2-6, 2013; San Francisco, CA.
26. Hujer, A. M.; Hujer, K. M.; Hall, T; Marzan, C.; Rangarajan, S.; Ecker, D. J.; Domitrovic, T. N.; Chen, L.; **Perez, F.**; Kreiswirth, B.; Fowler, V.; Chambers, H.; Bonomo, R. A. Using molecular diagnostics to decipher the genetic basis of antibiotic resistance in clinical isolates of gram-negative bacteria. Abstract 276 presented at: IDWeek 2013; October 2-6, 2013; San Francisco, CA.
27. **Perez, F.** Insights into the evolving impact of carbapenem resistant organisms in Northeast Ohio, United States, through the integration of molecular and epidemiologic approaches. Abstract 207 presented at: The 10th International Meeting on Microbial Markers (IMMEM-10); October 2-5, 2013; Institut Pasteur, Paris, France.
28. **Perez F.** Prithviraj G, Packer C. Augmenting the assessment of third year internal medicine clerkship students through oral examinations. Abstract presented at the Case Western Reserve University School of Medicine Education Retreat, March 6, 2014, Cleveland, OH.
29. Pyelonephritis In pregnancy caused by carbapenem-resistant Enterobacteriaceae (CRE): an emerging community infection? A. Khatri, N. Naeger Murphy, P. Wiest, M. Osborn, K. Garber, M. Hecker, S. D. Rudin, D. van Duin, **F. Perez,** R. A. Bonomo. Abstract L-1069 presented at: The 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 5-9, 2014; Washington, DC.
30. Outbreak Analysis of Enterobacter cloacae: hsp60 compares favorably to rep-PCR. R. A. Viau, L. Kiedrowski, **F. Perez, D.** Marchaim, D. Guerrero, K. Kaye, M. V. Villegas, R. A. Bonomo; Abstract K-1676 presented at: The 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 5-9, 2014; Washington, DC.
31. The complex epidemiology of carbapenem-resistant Enterobacter species. K. Amity, T. Lazarovitch, B. Ackerman, J. R. Coyle, R. Zaidenstein, **F. Perez,** R. A. Bonomo, K. S. Kaye, D. Marchaim. Abstract K-1030 presented at: The 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 5-9, 2014; Washington, DC.

32. Impact of ST258 *Klebsiella pneumoniae* harboring KPC in the Great Lakes region: insights from the Consortium on Resistance against Carbapenems in *K. pneumoniae* (CRaCKle). D. van Duin, **F. Perez**, S. D. Rudin, E. Cober, S. S. Richter, R. A. Salata, R. C. Kalayjian, K. S. Kaye, R. A. Bonomo. Abstract C-1877 presented at: The 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 5-9, 2014; Washington, DC.
33. The HHZ (High Heterogeneity Zone) Region of the *Klebsiella pneumoniae* (Kp) Genome: a Marker for Clinical and Epidemiologic Tracking. M. S. Ramirez, S. Johnson, G. Xie, **F. Perez**, D. Van Duin, M. Jacobs, K. Davenport, R. A. Bonomo, P. Chain, M. Tolmasky; Abstract C-1876 presented at: The 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 5-9, 2014; Washington, DC.
34. Molecular Characterization of Enterobacter Cloacae Complex (ecc) Harboring bla_{KPC} in Colombia (COL). E. De La Cadena, J. Muñoz, A. Correa, **F. Perez**, C. Hernandez, F. Rosso, C. Llanos, L. Uribe, M. Muñoz, M. Solarte, L. Matta, L. Rojas, R. A. Bonomo, M. V. Villegas; Abstract C-078 presented at: The 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 5-9, 2014; Washington, DC.
35. Temporal trends among ST258 *Klebsiella pneumoniae* strains harboring bla_{KPC} (KPC-Kp) in the Great Lakes region: insights from molecular surveillance. **F. Perez**, S. D. Rudin, E. Cober, S. Richter, R. C. Kalayjian, R. A. Salata, D. Marchaim, K. S. Kaye, M. R. Jacobs, A. Endimiani, R. A. Bonomo, D. van Duin. Abstract C-075 presented at: The 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 5-9, 2014; Washington, DC.
36. Summers N, Wilson B, Bonomo RA, **Perez F**. Are Patients with Spinal Cord Injury (SCI) a Unique Population? The Clinical Spectrum of *Pseudomonas aeruginosa* (Pa) Infection and Colonization in a Veterans Affairs Referral Center. Abstract presented at IDWeek 2015, October 7-11, 2015, San Diego CA.
37. Moore L, **Perez F**, Burant C, Sims S. The Use of Oral fosfomycin in Veterans for the Treatment of Urinary Tract Infections Caused by Multidrug-Resistant Gram-Negative Organisms. Abstract presented at IDWeek 2015, October 7-11, 2015, San Diego CA.
38. D Van Duin, **F Perez**, E Cober, SS Richter, R Kalayjian, Salata F, Scalera N, Watkins RR, Doi Y, Evans S, Vance G Fowler VG, Kaye KS, Rudin SD, Hujer KM, Hujer AM, Bonomo RA, Moody J. The Movement of Carbapenem-Resistant *Klebsiella pneumoniae* Among Healthcare Facilities: A Network Analysis. Abstract presented at IDWeek 2015, October 7-11, 2015, San Diego CA.
39. Salim M, **Perez F**, Cober E, Richter SS, Kalayjian R, Salata R, Scalera N, Watkins RR, Doi Y, Evans S, Fowler VG. Colistin Resistance in Patients with Carbapenem-Resistant *Klebsiella pneumoniae* Is Associated with Increased Mortality. Abstract presented at IDWeek 2015, October 7-11, 2015, San Diego CA.
40. Wilson B, Banks R, Carter R, Jump RL and **Perez F**. Cluster Analysis Reveals Unexpected Patterns in Pneumococcal Polysaccharide Vaccination Coverage. Society for Healthcare Epidemiology of America (SHEA) Spring 2016 Conference. May 18-21, 2016. Atlanta, GA.
41. Banks R, Wilson B, Carter R, Montpetite M, **Perez F** and Jump RL. A “Virtual Clinic” Improves Pneumococcal Vaccination Among Patients with HIV at a VA Medical Center. Society for Healthcare Epidemiology of America (SHEA) Spring 2016 Conference. May 18-21, 2016. Atlanta, GA.
42. Rudd K, Sims S, Wilson B, Hirsch A, Perez F, Stiefel U. Molecular Diagnostics Can Lead to Early Optimization of Antimicrobial Therapy for Staphylococcal Bacteremia: Experience at a Large Tertiary-Care VA Medical Center. Abstract presented at IDWeek 2016, October 26-30, 2016, New Orleans LA.
43. Rojas LJ, Marshall SM, Cober E, Richter SS, **Perez F**, Salata RA, Kalayjian R, Watkins RR, Doi Y, Kaye KS, Evans S, Fowler VG, Van Duin D, Bonomo RA; Molecular Analysis of Colistin Resistance Among *Klebsiella pneumoniae* Producing K pneumoniae Carbapenemase: Heterogeneity of Genetic Mechanisms. Abstract presented at IDWeek 2016, October 26-30, 2016, New Orleans LA.
44. Henig O, Van Duin D, Cober E, Richter SS, **Perez F**, Salata R, Kalayjian R, Watkins R, Doi Y, Evans S, Fowler VG. Epidemiology and Management of Skin and Soft Tissue Infection (SSTI) Due to Carbapenem-Resistant Enterobacteriaceae: A Report from The Consortium on Resistance against Carbapenems in *Klebsiella pneumoniae* (CRaCKle). Abstract presented at IDWeek 2016, October 26-30, 2016, New Orleans LA.
45. Bartley P, Santos C, Moretto V, Ferreira V, Domitrovic TN, Ponce-Terashima R, Reis M, Navas M, Barbosa L, **Perez F**, Blanton R. Fecal Contamination Contributes to the “Resistome” of Urban Surface Waters in Northeast Brazil. Abstract presented at IDWeek 2016, October 26-30, 2016, New Orleans LA.
46. Rosa R, Rudin SS, Rojas LJ, Perez-Cardona A, Aragon L, Nicolau DP, **Perez F**, Bonomo RA, Martinez O, Camargo J, Abbo L. Application of "Precision Medicine" Through the Molecular Characterization of Extensively Drug Resistant (XDR) *Klebsiella pneumoniae* in a Multivisceral Transplant Candidate Abstract presented at IDWeek 2016, October 26-30, 2016, New Orleans LA.

47. El Chakhtoura NG, Saade E, Wilson W, **Perez F**, Papp-Wallace K, Bonomo RA; A 17-Year Nationwide Study of Burkholderia cepacia Complex (Bcc) Blood Stream Infections (BSIs) Among Patients in the Veterans Health Administration (VHA). Abstract presented at IDWeek 2016, October 26-30, 2016, New Orleans LA.
48. Wilson B, Banks R, Jump R, **Perez F**; A Decade of Invasive Pneumococcal Disease in Ohio Veterans: Challenges in Resistance and Vaccination. Abstract presented at IDWeek 2016, October 26-30, 2016, New Orleans LA.
49. A Iovleva, **F Perez**, SH Marshall, AM Hujer, MR Jacobs, U Stiefel, A Ray, Bonomo RA. Ceftazidime/Avibactam and Ceftolozane/Tazobactam in Treatment of Pulmonary Infections by Imipenem Resistant Pseudomonas aeruginosa. Abstract presented at IDWeek 2016, October 26-30, 2016, New Orleans LA.
50. A Petrarca, C Burant, U Stiefel, **F Perez**, S Sims. Outcomes of Bloodstream Infections (BSI) Caused by Coagulase-Negative Staphylococcus (CoNS) With Elevated Minimum Inhibitory Concentration (MIC) to Vancomycin at a Tertiary Care Veterans Affairs (VA) Medical Center. Abstract presented at IDWeek 2016, October 26-30, 2016, New Orleans LA.
51. B Wilson, F Perez, E Saade, CJ Donskey. Healthcare Facility-Associated *Clostridium difficile* Infection in Hospitalized Patients Receiving Intravenous Beta-Lactam Antibiotics in the Veterans Affairs Healthcare System (VHA). Abstract presented at IDWeek 2016, October 26-30, 2016, New Orleans LA.
52. **F Perez**, B Wilson, S Patel, E Saade, CJ Donskey, RA Bonomo. Carbapenem-Resistant *Enterobacteriaceae* in the Veterans Health Administration: A "Second Epidemic" of Carbapenem Resistance Among Enterobacter cloacae After That of Klebsiella pneumoniae. Abstract presented at IDWeek 2016, October 26-30, 2016, New Orleans LA.
53. Evans S, Thuy Tran TT, AHujer AM, Hill C, Hujer KM, Mediavilla JR, Manca C, Domitrovic TN, Kreiswirth BN, Patel R, Jacobs MR, **Perez F**, Chen L, Sampath R, Hall T, Marzan C, Fowler VG, Chambers H, Bonomo RA. Choosing Ceftazidime/Avibactam and Ceftolozane/Tazobactam as Empiric Therapies against Pseudomonas aeruginosa (Pa) using Rapid Molecular Diagnostics (RMDs): PRIMERS IV. Abstract presented at IDWeek 2016, October 26-30, 2016, New Orleans LA.
54. Munita J, Aitken S, **Perez F**, Rosa R, Jain R, Nigo M, Wanger A, Araos R, Tran T, Tverdek FP, Shimose L. Ceftolozane-Tazobactam (C/T) for Severe Infections Caused by Carbapenem-Resistant Pseudomonas. Abstract presented at IDWeek 2016, October 26-30, 2016, New Orleans LA.
55. Banks R, Wilson B, Carter R, **Perez F** and Jump RL. A Virtual Clinic Increases Pneumococcal Vaccinations In Veterans with Chronic Lymphocytic Leukemia. 2016 Gerontological Society of America Annual Scientific Meeting, November 16-20, 2016. New Orleans, LA
56. Wilson B, Banks R, Jump R and **Perez F**. Treatment of Non-Invasive Pneumococcal Pneumonia Diagnosed by Urinary Antigen and Bacterial Cultures. SHEA Spring 2017 Conference. March 29-31, St. Louis, MO
57. Boshe A., Cober E., **Perez F.**, Salata R., Kalayjian R., Richter S., Watkins, Doi Y., Kaye, K. S., Evans S., Fowler V, Bonomo R., van Duin D. Trimethoprim/sulfamethoxazole in the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae. American Society for Microbiology Microbe 2017, June 1-5 2017. New Orleans, LA.
58. Patel S., Akpoji U., Wilson B. M., Hirsch A., Sims S., **Perez F.**; Turnaround Time of Procalcitonin Result is Key to Improve Antibiotic Use at a VA Medical Center. American Society for Microbiology Microbe 2017, June 1-5 2017. New Orleans, LA.
59. Akpoji U., Patel S., Wilson B. M., Hirsch A., Sims S., **Perez F**. Ordering and Interpretation of Procalcitonin for Suspected Bacterial Infections at the Cleveland VA Medical Center. American Society for Microbiology Microbe 2017, June 1-5 2017. New Orleans, LA.
60. A. Kanwar A, S. H. Marshall SH, F. **Perez F.**, Tomas M., El Chakhtoura N. G., Jacobs M., Hujer A. M., Domitrovic T. N., Rudin S. D., Rudin, Kreiswirth B. N., Chen L., R. A. Bonomo RA. Treatment-Emergent Colistin Resistance (COL-R) in Klebsiella pneumoniae Carbapenemase (KPC) Producing Klebsiella pneumoniae (Kp). American Society for Microbiology Microbe 2017, June 1-5 2017. New Orleans, LA.
61. El Chakhtoura N.G., Wilson B. M., Saade E. A., **Perez F.**, Bonomo R. A.; Mortality Rates of Carbapenem-Non-Susceptible Enterobacter cloacae Complex (CNS-Ent) and Klebsiella pneumoniae (CNS-Kp) Bloodstream Infections (BSI) in the Veterans Health Administration (VHA): The Clinical Impact of the "Second Epidemic". American Society for Microbiology Microbe 2017, June 1-5 2017. New Orleans, LA.
62. El Chakhtoura N.G., Wilson B. M., Saade E. A., **Perez F**. A Hidden Menace: Oxacillin-Resistant Staphylococcus lugdunensis (SL) at the Veterans Health Administration (VHA) between 2006 and 2015. American Society for Microbiology Microbe 2017, June 1-5 2017. New Orleans, LA.
63. Serrano R, Matheu M, **Perez F**, Patterson JE, Rudin SD, Bonomo RA, Traugott K, Cadena JA. Molecular and Microbiological Evaluation of Carbapenem-resistant Enterobacteriaceae (CRE) at Two Centers in Texas. Abstract presented at IDWeek 2017, October 4-8, 2017, San Diego CA.

64. Sachin Patel S, Wilson B, El Chakhtoura NG, Saade E, Donskey CJ, Bonomo RA, **Perez F**. Trends in the incidence of bacteremia with carbapenem non-susceptible *Acinetobacter* spp. in patients from the US Veterans Health Administration, 2000-2015. Abstract presented at IDWeek 2017, October 4-8, 2017, San Diego CA.
65. Kanwar A, **Perez F**, Donskey CJ. Improving Fellows' Presentations at Case-Conference: A Quality Improvement Initiative. Abstract presented at IDWeek 2017, October 4-8, 2017, San Diego CA.
66. Akpoji U, Stiefel U, **Perez F**, Fernandez J, Burant C, Sims S. Don't Ask, Don't Tell: Quality of β -lactam Allergy Assessment in Patients with Methicillin-Susceptible *Staphylococcus aureus* (MSSA) Infections at a Tertiary-Care VA Medical Center. Abstract presented at IDWeek 2017, October 4-8, 2017, San Diego CA.
67. N. El Chakhtoura, B. Wilson, B. Gutiérrez-Gutiérrez, E. Saade, C. Donskey, **F. Perez**, J. Rodríguez-Baño, R. Bonomo. INCREMENT score predicts mortality among patients with carbapenem non-susceptible *Enterobacter cloacae* complex (CNS-Ecc) bloodstream infection (BSI) in the United States Veterans Health Administration (VHA). Abstract presented at the European Congress on Clinical Microbiology and Infectious Diseases 2018, April 20-23, 2018, Madrid, Spain.
68. Pogue JM, Kaye KS, Veve M, Gerlach A, Patel TS, Davis SL, Chaung E, Ray A, Puzniak L, Bonomo RA, **Perez F**; 2406. "Real-world" Treatment of Multidrug-Resistant (MDR) or Extensively Drug-Resistant (XDR) *P. aeruginosa* Infections with Ceftolozane/Tazobactam (C/T) vs. a Polymyxin or Aminoglycoside (Poly/AG)-based Regimen: A Multicenter Comparative Effectiveness Study. Abstract presented at IDWeek 2018, October 3-7, 2018, San Francisco, CA.
69. Abbo LM, Yasmin M, Marshall SH, **Perez F**, Corzo-Pedrosa M, Camargo JF, Simkins J, Aragon L, Anjan S, Morris MI, Brozzi N, Loebe M, Fulmer J, Sinha N, Martinez O, Perez-Cardona A, Colin A, Cloke C, Bonomo RA; 2395. Mechanism-Based-Susceptibility Testing (MBST) Using Disc Diffusion Assays (DDA) to Guide Treatment of Multidrug- and Extensively Drug-Resistant *Pseudomonas aeruginosa* (MDR-XDR-*Pa*) in a Cystic Fibrosis (CF) Lung Transplant Recipient; Are We Ready for Combination Therapy vs. MDR-XDR-*Pa*? Abstract presented at IDWeek 2018, October 3-7, 2018, San Francisco, CA.
70. Freshwater D, Stiefel U, **Perez F**, Akpoji A, Hirsch A, Burant C, Navas M, Sims S; 2024. Modeled Impact of Rapid Diagnostics on the Treatment of Gram-Negative Bacteremia at a Tertiary-Care VA Medical Center. Abstract presented at IDWeek 2018, October 3-7, 2018, San Francisco, CA.
71. Masroujeh R, Elie Saade E, Brigid Wilson B, Federico **Perez F**, Robert A Bonomo RA; 1483. Pleural Empyema Caused by *Stenotrophomonas maltophilia* in a National Cohort of Hospitalized Veterans. Abstract presented at IDWeek 2018, October 3-7, 2018, San Francisco, CA.
72. Rojas LJ, Marshall SH, Rivas LM, Spencer M, Rutter J, Jacobs MR, **Perez F**, Coria P, Valdivieso F, Araos Bralic R, Munita JM, Bonomo RA; 2560. Multispecies Outbreak of KPC-2 Producing *Enterobacteriaceae* in a Chilean Pediatric Hospital. Abstract presented at IDWeek 2018, October 3-7, 2018, San Francisco, CA.
73. Yasmin M, Chen L, Marshall SH, Kreiswirth BN, **Perez F**, Bonomo RA; 700. Identification and Whole-Genome Sequencing (WGS) of Meropenem-Vaborbactam (MV) Resistant *Klebsiella pneumoniae* (MVRKP) Among Patients Without Prior Exposure to MV: Collateral Damage. Abstract presented at IDWeek 2018, October 3-7, 2018, San Francisco, CA.
74. Saade E, Dousa KM, Wilson B, **Perez F**, Donskey CJ; 1179. Incidence of Bacteremia and Bacteriuria with Antibiotic-Resistant *Enterobacteriaceae* After Transrectal Ultrasound-Guided Biopsy of the Prostate (TRUSBP). Abstract presented at IDWeek 2018, October 3-7, 2018, San Francisco, CA.
75. Viau R, Wilson V, Evans SR, **Perez F**, Chambers HF, Fowler VG, Kreiswirth BN, Bonomo RA, ARLG; 1041. How Do Healthcare Providers Approach Empiric β -Lactam (BL) Treatment of Bloodstream Infections (BSI) Caused by Gram-Negative Rods (GNRs)? Analysis of *Escherichia coli* and *Klebsiella pneumoniae* BSI From the Veterans Health Administration (VHA). Abstract presented at IDWeek 2018, October 3-7, 2018, San Francisco, CA.
76. El Chakhtoura NG, Wilson B, Gutiérrez-Gutiérrez B, **Perez F**, Saade S, Donskey CJ, Rodríguez-Bano J, Bonomo RA; 2397. Comparing Predictive Performance of INCREMENT Scores on Mortality Among Patients with Carbapenem-Non-Susceptible (CNS) *Klebsiella pneumoniae* (*Kp*) and *Enterobacter cloacae* Complex (*Ecc*) Bloodstream Infections (BSI) in the Veterans Health Administration (VHA). Abstract presented at IDWeek 2018, October 3-7, 2018, San Francisco, CA.
77. Saade E, Wilson W, El Chakhtoura NG, Viau R, **Perez F**, Lodise T, Bonomo RA; 2409. Drug-Induced Liver Injury (DILI) in a National Cohort of Hospitalized Patients Treated with Aztreonam and Ceftazidime. Abstract presented at IDWeek 2018, October 3-7, 2018, San Francisco, CA.
78. Wilson B, Viau R, **Perez F**, Jiang H, Fowler VG, Chambers HF, Kreiswirth BN, Bonomo RA, Evans SR, ARLG; 1757. Using the Desirability of Outcome Ranking for Management of Antimicrobial Therapy (DOOR-MAT) to Assess Antibiotic Therapy Guided by Rapid Molecular Diagnostics (RMD) in Bloodstream Infection (BSI) Caused

by *Escherichia coli* and *Klebsiella pneumoniae*. Abstract presented at IDWeek 2018, October 3-7, 2018, San Francisco, CA.

79. Viau R, Wilson B, Evans SR, **Perez F**, Fowler VG, Chambers HF, Kreiswirth BN, Patel R, Banerjee R, Bonomo RA, ARLG; 1052. Do Healthcare Providers De-Escalate β -Lactam (BL) Antibiotic Therapy Based on Results of Antibiotic Susceptibility Testing (AST)? Analysis of Bloodstream Infections (BSI) Caused by *Escherichia coli* and *Klebsiella pneumoniae* From the Veterans Health Administration (VHA). Abstract presented at IDWeek 2018, October 3-7, 2018, San Francisco, CA.
80. Jump R, Wilson B, Banks R, Baechle D, Briggs J, Song S, Zappernick T and **Perez F**. The Burden of Invasive Group B Streptococcal Infections in the Veterans Health Administration. Society for Healthcare Epidemiology of America (SHEA) Spring 2019 Conference. April 24-26, 2019. Boston, MA.
81. Briggs J, Wilson B, Zappernick T, Banks R, Baechle D, Song S, Jump RL and **Perez F**. Variations in the frequency and impact of polymicrobial cultures in adults with invasive Group B Streptococcal (GBS) infection at the US Veterans Health Administration. ID Week: A Joint Meeting of IDSA, SHEA, HIVMA, and PIDS. October 2-6, 2019. Washington, DC.
82. Zappernick T, Wilson B, Banks R, Baechle D, Song S, Briggs J, Jump RL and **Perez F**. Characteristics and Outcomes of Veterans with Invasive Group B Streptococcal Infection Vary with the Type of Syndrome. ID Week: A Joint Meeting of IDSA, SHEA, HIVMA, and PIDS. October 2-6, 2019. Washington, DC.
83. Wilson B, Zappernick T, Banks R, Baechle D, Briggs J, Song S, **Perez F** and Jump RL. Elevated Risk of Invasive Group B Streptococcal Infection Among Veterans with Poorly Controlled Diabetes Mellitus or at Extremes for Body Mass Index. ID Week: A Joint Meeting of IDSA, SHEA, HIVMA, and PIDS. October 2-6, 2019. Washington, DC.
84. Nguyen D, Lisgaris M, Vasireddy S, Wallace R, **Perez F**, and Rhoads D. A Novel Rapidly Growing Mycobacteria Species Causing Soft Tissue and Orthopedic Hardware Infection After Trauma. ID Week: A Joint Meeting of IDSA, SHEA, HIVMA, and PIDS. October 2-6, 2019. Washington, DC.
85. Rojas L, Marshall S, Yasmin M, Rudin S, **Perez F**, Donskey C, Hecker M, Bonomo RA. Reversal of carbapenem and amikacin susceptibilities in isogenic *Klebsiella pneumoniae* from a patient with persistent bacteriuria. ID Week: A Joint Meeting of IDSA, SHEA, HIVMA, and PIDS. October 2-6, 2019. Washington, DC.
86. Yasmin M, Adams M, Marshall S, Abbo L, Benjamino J, Rojas L, Scott J, Jacobs MR, Rhoads D, Perez-Cardona A, Martinez O, **Perez F**, Bonomo RA. Genomic evolution and progression of antimicrobial resistance in a series of XDR Pa isolates from a cystic fibrosis lung transplant recipient. ID Week: A Joint Meeting of IDSA, SHEA, HIVMA, and PIDS. October 2-6, 2019. Washington, DC.
87. Yasmin M, Marshall S, Jacobs MR, Rhoads D, Rojas L, **Perez F**, Bonomo RA. Meropenem/vaborbactam in vitro activity against CRKP isolates with OMP mutations. ID Week: A Joint Meeting of IDSA, SHEA, HIVMA, and PIDS. October 2-6, 2019. Washington, DC.
88. Goldberg J, Bethel C, Hujer A, Hujer K, Marshall S, Papp-Wallace K, **Perez F**, Spencer E, Hoyer D, Plummer M, Bonomo RA. In vitro activity of a new generation oxopyrazole antibiotic against *Acinetobacter* spp. ID Week: A Joint Meeting of IDSA, SHEA, HIVMA, and PIDS. October 2-6, 2019. Washington, DC.
89. Goldberg J, Bethel C, Hujer A, Hujer K, Marshall S, Papp-Wallace K, **Perez F**, Spencer E, Hoyer D, Plummer M, Bonomo RA. In vitro activity of a new generation oxopyrazole antibiotic against MDR Gram negative bacilli. ID Week: A Joint Meeting of IDSA, SHEA, HIVMA, and PIDS. October 2-6, 2019. Washington, DC.
90. Christian R, Sims S, Zappernick T, Wilson B, **Perez F**, Bonomo RA and Jump RL. Influence of Microbiological Culture Results on Antibiotic Choice for Veterans with Hospital-Acquired Pneumonia. ID Week: A Joint Meeting of IDSA, SHEA, HIVMA, and PIDS. October 2-6, 2019. Washington, DC.
91. Wilson BM, Bej T, Akpoji U, Banks R, Briggs J, Song S, Jump RLP, **Perez F**. In outpatient clinics serving Veterans, antibiotic prescriptions precede a minority of antibiotic-associated adverse events. ID Week: A Joint Meeting of IDSA, SHEA, HIVMA, and PIDS. October 21-25, 2020. Philadelphia, PA.
92. Bej T, Wilson BM, Banks R, Briggs J, Song S, **Perez F**, Jump RLP. Invasive and Non-Invasive Osteomyelitis Caused by Group B Streptococcus Infection Among Veterans. ID Week: A Joint Meeting of IDSA, SHEA, HIVMA, and PIDS. October 21-25, 2020. Philadelphia, PA.
93. Song S, Bej T, Wilson BM, Banks R, Briggs J, Jump RLP, **Perez F**. Incidence of Community Acquired Pneumonia by Age and Comorbid Conditions in the Veterans Health Administration (VHA). ID Week: A Joint Meeting of IDSA, SHEA, HIVMA, and PIDS. October 21-25, 2020. Philadelphia, PA.
94. Alabdely MH, Kothadia S, Bej TA, Wilson BM, Song S, Akpoji U, **Perez F**, and Jump RLP. Absence of Racial or Ethnic Disparities in COVID-19 Survival among Residents of US Veterans Affairs Community Living Centers

- (CLCs). Society for Healthcare Epidemiology of America (SHEA) Spring 2022 Conference. April 12-214, 2022. Colorado Springs, CO.
95. Akpoji UC, Wilson BM, Chengsupanimit T, Song S, Bej T, Jump RLP, and **Perez F**. In Veteran outpatients, antibiotics remain significant risk factor for community-acquired *Clostridioides difficile* infection. Society for Healthcare Epidemiology of America (SHEA) Spring 2022 Conference. April 12-214, 2022. Colorado Springs, CO.
 96. Mongilardi, N, Wilson BM, Bej T, Song S, Jump RLP, **Perez F**, and Akpoji U. Outpatient Antibiotic Use for Common Infectious Diagnoses: Patterns in Telehealth During the Emergence of COVID-19. Society for Healthcare Epidemiology of America (SHEA) Spring 2022 Conference. April 12-214, 2022. Colorado Springs, CO. –Top Poster Abstract Award
 97. Kothadia S, Wilson BM, **Perez F**, Bonomo RA. Co-infections in Hospitalized COVID-19 Patients are Associated with High Mortality: Need for Improved Diagnostic Tools. Society for Healthcare Epidemiology of America (SHEA) Spring 2022 Conference. April 12-214, 2022. Colorado Springs, CO. –Top Poster Abstract Award
 98. Hojat L, Wilson BM, **Perez F**, Bonomo RA. *Pseudomonas aeruginosa* Bloodstream Infection Mortality and Resistance Trends in the Veterans Health Administration System. Society for Healthcare Epidemiology of America (SHEA) Spring 2022 Conference. April 12-214, 2022. Colorado Springs, CO.
 99. Hojat L, Wilson BM, **Perez F**, Bonomo RA. Impact of COVID-19 on Mortality Associated with *Pseudomonas aeruginosa* Bloodstream Infection in the Veterans Health Administration System. ID Week: A Joint Meeting of IDSA, SHEA, HIVMA, and PIDS. October 19-23, 2022. Washington, DC.
 100. Yasmin M, Chen L, Marshall S, Rhoads D, Jacobs MR, Rojas LJ, **Perez F**, Hujer AM, Kreiswirth BN, Bonomo RA. Evaluation of Meropenem-vaborbactam susceptibility and underlying resistance mechanisms among clinical KPC-producing *Klebsiella pneumoniae*. ID Week: A Joint Meeting of IDSA, SHEA, HIVMA, and PIDS. October 19-23, 2022. Washington, DC.